Регистрация
Расширенный поиск
RU EN
Главная
Последний номер
Архив номеров
Подписка
Контакты
Российское диализное общество

Просмотр статьи

<< Вернуться к списку статей журнала

Том 16 №1 - Приложение 2014 год - Нефрология и диализ

Клинические практические рекомендации KDIGO по лечению гломерулонефритов


Даниел Каттран Джон Фили Теренс Кук Фернандо Фервенца Йорген Флеге Дебби Джипсон Ричард Глассок Элизабет Ходсон Вивекананд Йаха Филип Кам-Тао Ли Зи-Хонг Ли Серджио Муццано Патрик Нахман Мануэль Прага Джай Радакришнан Брэд Ровин Стефан Троянов Джек Ветцельс

Аннотация: Kidney International supplements Volume 2/ issue 2/ June 2012 http://www.kidney-international.org Перевод Л.С. Бирюковой, Е.В. Захаровой и Е.В. Кальяновой под общей редакцией Е.В. Захаровой Перевод выполнен по инициативе РДО и одобрен KDIGO Все права принадлежат KDIGO, воспроизведение возможно только с разрешения KDIGO и РДО Резюме Клинические практические рекомендации по лечению гломерулонефритов (ГН) 2011 г., разработанные инициативной группой по улучшению глобальных исходов заболеваний почек [Kidney Disease: Improving Global Outcomes (KDIGO)], имеют цель содействовать практическим врачам в оказании помощи взрослым пациентам и детям с ГН. Разработке рекомендаций предшествовал длительный процесс детального изучения доказательств и предварительного анализа. Рекомендации содержат разделы, посвященные различным гломерулярным заболеваниям: стероид-чувствительному нефротическому синдрому и стероид-резистентному нефротическому синдрому у детей; болезни минимальных изменений; идиопатическому фокальному сегментарному гломерулосклерозу; идиопатической мембранозной нефропатии; мембранопролиферативному гломерулонефриту; гломерулонефриту, ассоциированному с инфекционными заболеваниями; ИГА-нефропатии; нефриту при пурпуре Геноха-Шенляйна; волчаночному нефриту; пауци-иммунному фокальному и сегментарному некротизирующему гломерулонефриту; анти-ГБМ антительному гломерулонефриту. Подходы к лечению освещены в каждом разделе, рекомендации основаны на результатах систематического обзора проведенных исследований. Оценка качества доказательности и силы рекомендаций основана на выделении соответствующих степеней. Кроме того, обсуждаются ограничения доказательной силы и высказываются предложения по проведению дальнейших исследований. ЦИТИРОВАНИЕ При цитировании этого документа должен использоваться следующий формат: Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney inter., Suppl. 2012; 2: 139-274.

Для цитирования: Даниел Каттран, Джон Фили, Теренс Кук, Фернандо Фервенца, Йорген Флеге, Дебби Джипсон, Ричард Глассок, Элизабет Ходсон, Вивекананд Йаха, Филип Кам-Тао Ли, Зи-Хонг Ли, Серджио Муццано, Патрик Нахман, Мануэль Прага, Джай Радакришнан, Брэд Ровин, Стефан Троянов, Джек Ветцельс Клинические практические рекомендации KDIGO по лечению гломерулонефритов. Нефрология и диализ. 2014. 16(1):1-163. doi:

Весь текст



Ключевые слова: Клинические практические рекомендации KDIGO, гломерулонефриты, нефротический синдром, рекомендации, основанные на доказательствах, систематический обзор, Clinical Practice Guideline, KDIGO, glomerulonephritis, nephrotic syndrome, evidence-based recommendation, systematic review

Список литературы:
  1. Corwin H.L., Schwartz M.M., Lewis E.J. The importance of sample size in the interpretation of the renal biopsy. Am. J. Nephrol. 1988; 8: 85-89.
  2. Price C.P., Newall R.G., Boyd J.C. Use of protein: creatinine ratiomeasurements on random urine samples for prediction of significantproteinuria: a systematic review. Clin. Chem. 2005; 51: 1577-1586.
  3. Fine D.M., Ziegenbein M., Petri M. et al. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Kidney Int. 2009; 76: 1284-1288.
  4. Branten A.J., Vervoort G., Wetzels J.F. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol. Dial. Transplant. 2005; 20: 707-711.
  5. Botev R., Mallie J.P., Couchoud С. et al. Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance. Clin. J. Am. Soc. Nephrol. 2009; 4: 899-906.
  6. Rovin B.H., McKinley A.M., Birmingham D.J. Can we personalize treatment for kidney diseases? Clin. J. Am. Soc. Nephrol. 2009; 4: 1670-1676.
  7. Upadhyay A., Earley A., Haynes S.M. et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann. Intern. Med. 2011; 154: 541-548.
  8. Agarwal A., Haddad N., Hebert L.A. Progression of kidney disease: diagnosis and management. In: Molony D.A., Craig J.C. (eds). Evidence-based Nephrology, 1st edn. John Wiley & Sons: Hoboken, NJ, 2008; 311-322.
  9. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114 (Suppl 2): 555-576.
  10. Wuhl E., Trivelli A., Picca S. et al. Strict blood-pressure control and progression of renal failure in children. N. Engl. J. Med. 2009; 361: 1639-1650.
  11. Ogi M., Yokoyama H., Tomosugi N. et al. Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am. J. Kidney Dis. 1994; 24: 427-436.
  12. Furth S.L., Arbus G.S., Hogg R. et al. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. J. Pediatr. 2003; 142: 145-148.
  13. Philibert D., Cattran D. Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? Nat. Clin. Pract. Nephrol. 2008; 4: 550-559.
  14. McKinney P.A., Feltbower R.G., Brocklebank J.T. et al. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatr. Nephrol. 2001; 16: 1040-1044.
  15. A Report of the International Study of Kidney Disease in Children. Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. Kidney Int. 1981; 20: 765-771.
  16. Fakhouri F., Bocquet N., Taupin P. et al. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am. J. Kidney Dis. 2003; 41: 550-557.
  17. Koskimies O., Vilska J., Rapola J. et al. Long-term outcome of primary nephrotic syndrome. Arch. Dis. Child. 1982; 57: 544-548.
  18. Tarshish P., Tobin J.N., Bernstein J. et al. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J. Am. Soc. Nephrol. 1997; 8: 769-776.
  19. Arneil G.C. 164 children with nephrosis. Lancet. 1961; 2: 1103-1110.
  20. Ruth E.M., Kemper M.J., Leumann E.P. et al. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J. Pediatr. 2005; 147: 202-207.
  21. Bhimma R., Coovadia H.M., Adhikari M. Nephrotic syndrome in South African children: changing perspectives over 20 years. Pediatr. Nephrol. 1997; 11: 429-434.
  22. Kim J.S., Bellew C.A., Silverstein D.M. et al. High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int. 2005; 68: 1275-1281.
  23. Arneil G.C. The nephrotic syndrome. Pediatr. Clin. North Am. 1971; 18: 547-559.
  24. Alternate-day versus intermittent prednisone in frequently relapsing nephrotic syndrome. A report of ‘Arbetsgemeinschaft fur Padiatrische Nephrologie’. Lancet. 1979; 1: 401-403.
  25. Hodson E.M., Knight J.F., Willis N.S. et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst. Rev. 2005: CD001533.
  26. Feber J., Al-Matrafi J., Farhadi E. et al. Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent? Pediatr. Nephrol. 2009; 24: 1027-1031.
  27. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J. Pediatr. 1981; 98: 561-564.
  28. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Lancet. 1988; 1: 380-383.
  29. Alternate-day prednisone is more effective than intermittent prednisone in frequently relapsing nephrotic syndrome. A report of ‘Arbeitsgemeinschaft fur Padiatrische Nephrologie’. Eur. J. Pediatr. 1981; 135: 229-237.
  30. Broyer M., Guest G., Gagnadoux M.F. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J. Pediatr. 1992; 120: 721-725.
  31. Letavernier B., Letavernier E., Leroy S. et al. Prediction of high-degree steroid dependency in pediatric idiopathic nephrotic syndrome. Pediatr. Nephrol. 2008; 23: 2221-2226.
  32. Noer M.S. Predictors of relapse in steroid-sensitive nephrotic syndrome. Southeast. Asian J. Trop. Med. Public Health. 2005; 36: 1313-1320.
  33. Lewis M.A., Baildom E.M., Davis N. et al. Nephrotic syndrome: from toddlers to twenties. Lancet. 1989; 1: 255-259.
  34. Andersen R.F., Thrane N., Noergaard К. et al. Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome. Pediatr. Nephrol. 2010; 25: 1299-1304.
  35. Constantinescu A.R., Shah H.B., Foote E.F. et al. Predicting first-year relapses in children with nephrotic syndrome. Pediatrics. 2000; 105: 492-495.
  36. Abeyagunawardena A.S., Trompeter R.S. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial. Arch. Dis. Child. 2008; 93: 226-228.
  37. Gulati A., Sinha A., Sreenivas V. et al. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin. J. Am. Soc. Nephrol. 2011; 6: 63-69.
  38. Elzouki A.Y., Jaiswal O.P. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. Clin. Pediatr. (Phila). 1988; 27: 387-392.
  39. Consensus statement on management and audit potential for steroid responsive nephrotic syndrome. Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians. Arch. Dis. Child. 1994; 70: 151-157.
  40. Bagga A., AN U., Banerjee S. et al. Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr. 2008; 45: 203-214.
  41. Srivastava R.N., Vasudev A.S., Bagga A. et al. Long-term, low-dose prednisolone therapy in frequently relapsing nephrotic syndrome. Pediatr. Nephrol. 1992; 6: 247-250.
  42. Kyrieleis H.A., Lowik M.M., Pronk I. et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin. J. Am. Soc. Nephrol. 2009; 4: 1593-1600.
  43. Latta K., von Schnakenburg C., Ehrich J.H. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr. Nephrol. 2001; 16: 271-282.
  44. Niaudet P., Habib R., Tete M.J. et al. Cyclosporin in the treatment of idiopathic nephrotic syndrome in children. Pediatr. Nephrol. 1987; 1: 566-573.
  45. Boyer О., Moulder J.K., Grandin L. et al. Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndrome. Pediatr. Nephrol. 2008; 23: 575-580.
  46. Hino S., Takemura T., Okada M. et al. Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Am. J. Kidney. Dis. 1998; 31: 932-939.
  47. Leroy V., Baudouin V., Alberti С. et al. Growth in boys with idiopathic nephrotic syndrome on long-term cyclosporin and steroid treatment. Pediatr. Nephrol. 2009; 24: 2393-2400.
  48. Mown J.A., McCarthy E.T. Cyclosporine in glomerular disease. Semin. Nephrol. 1996; 16: 548-554.
  49. Hodson E.M., Willis N.S., Craig J.C. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst. Rev. 2008: CD002290.
  50. Kyrieleis H.A., Levtchenko E.N., Wetzels J.F. Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am. J. Kidney Dis. 2007; 49: 592-597.
  51. Azib S., Macher M.A., Kwon T. et al. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 2011; 26: 927-932.
  52. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft fur Padiatrische Nephrologie. Arch. Dis. Child. 1987; 62: 1102-1106.
  53. Williams S.A., Makker S.P., Ingelfinger J.R. et al. Long-term evaluation of chlorambucil plus prednisone in the idiopathic nephrotic syndrome of childhood. N. Engl. J. Med. 1980; 302: 929-933.
  54. Wetzels J.F. Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? Neth. J. Med. 2004; 62: 347-352.
  55. Miller D.G. Alkylating agents and human spermatogenesis. JAMA. 1971; 217: 1662-1665.
  56. Weiss R. Randomized double-blind placebo controlled, multi-center trial of levamisole for children with frequently relapsing/steroid dependent nephrotic syndrome (abstract). J. Am. Soc. Nephrol. 1993; 4: 289.
  57. Fu L.S., Shien C.Y., Chi C.S. Levamisole in steroid-sensitive nephrotic syndrome children with frequent relapses and/or steroid dependency: comparison of daily and every-other-day usage. Nephron Clin. Pract. 2004; 97: C137-C141.
  58. Hafeez F., Ahmed T.M., Samina U. Levamisole in steroid dependent and frequently relapsing nephrotic syndrome. J. Coll. Physicians. Surg. Рак. 2006; 16: 35-37.
  59. Kemper M.J., Amon O., Timmermann К. et al. The treatment with levamisole of frequently recurring steroid-sensitive idiopathic nephrotic syndrome in children. Dtsch. Med. Wochenschr. 1998; 123: 239-243.
  60. Palcoux J.B., Niaudet P., Goumy P. Side effects of levamisole in children with nephrosis. Pediatr. Nephrol. 1994; 8: 263-264.
  61. Niaudet P. Comparison of cyclosporin and chlorambucil in the treatment of steroid-dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr. Nephrol. 1992; 6: 1-3.
  62. Ponticelli C., Edefonti A., Ghio L. et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol. Dial. Transplant. 1993; 8: 1326-1332.
  63. Yoshioka K., Ohashi Y., Sakai T. et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000; 58: 317-324.
  64. El-Husseini A., El-Basuony F., Mahmoud I. et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol. Dial. Transplant. 2005; 20: 2433-2438.
  65. Hulton S.A., Neuhaus T.J., Dillon M.J. et al. Long-term cyclosporin A treatment of minimal-change nephrotic syndrome of childhood. Pediatr. Nephrol. 1994; 8: 401-403.
  66. Niaudet P., Broyer M., Habib R. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. Clin. Nephrol. 1991; 35 (Suppl 1): S31-S36.
  67. Ishikura K., Ikeda M., Hattori S. et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008; 73: 1167-1173.
  68. Filler G. How should microemulsified Cyclosporine A (Neoral) therapy in patients with nephrotic syndrome be monitored? Nephrol. Dial. Transplant. 2005; 20: 1032-1034.
  69. Sinha M.D., MacLeod R., Rigby E. et al. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol. Dial. Transplant. 2006; 21: 1848-1854.
  70. Dotsch J., Dittrich K., Plank С. et al. Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A? Nephrol. Dial. Transplant. 2006; 21: 1761-1763.
  71. lijima K., Hamahira K., Tanaka R. et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney. Int. 2002; 61: 1801-1805.
  72. Kranz B., Vester U., Buscher R. et al. Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years. Pediatr. Nephrol. 2008; 23: 581-586.
  73. El-Husseini A., El-Basuony F., Mahmoud I. et al. Impact of the cyclosporine-ketoconazole interaction in children with steroid-dependent idiopathic nephrotic syndrome. Eur. J. Clin. Pharmacol. 2006; 62: 3-8.
  74. Dorresteijn E.M., Kist-van Holthe J.E., Levtchenko E.N. et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr. Nephrol. 2008; 23: 2013-2020.
  75. Hogg R.J., Fitzgibbons L., Bruick J. et al. Clinical trial of mycophenolate mofetil (MMF) for frequent relapsing nephrotic syndrome in children (abstract). Pediatr. Nephrol. 2004; 19: C66.
  76. Afzal K., Bagga A., Menon S. et al. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 2007; 22: 2059-2065.
  77. Barletta G.M., Smoyer W.E., Bunchman Т.Е. et al. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome. Pediatr. Nephrol. 2003; 18: 833-837.
  78. Ettenger R., Bartosh S., Choi L. et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatr. Transplant. 2005; 9: 780-787.
  79. Ravani P., Magnasco A., Edefonti A. et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin. J. Am. Soc. Nephrol. 2011; 6: 1308-1315.
  80. Guigonis V., Dallocchio A., Baudouin V. et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr. Nephrol. 2008; 23: 1269-1279.
  81. Prytula A., lijima K., Kamei К. et al. Rituximab in refractory nephrotic syndrome. Pediatr. Nephrol. 2010; 25: 461-468.
  82. Chaumais M.C., Gamier A., Chalard F. et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr. Nephrol. 2009; 24: 1753-1755.
  83. Gulati S., Sharma A.P., Sharma R.K. et al. Do current recommendations for kidney biopsy in nephrotic syndrome need modifications? Pediatr. Nephrol. 2002; 17: 404-408.
  84. Gulati S., Sural S., Sharma R.K. et al. Spectrum of adolescent-onset nephrotic syndrome in Indian children. Pediatr. Nephrol. 2001; 16: 1045-1048.
  85. Baqi N., Singh A., Balachandra S. et al. The paucity of minimal change disease in adolescents with primary nephrotic syndrome. Pediatr. Nephrol. 1998; 12: 105-107.
  86. Gipson D.S., Chin H., Presler T.P. et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr. Nephrol. 2006; 21: 344-349.
  87. Gorensek M.J., Lebel M.H., Nelson J.D. Peritonitis in children with nephrotic syndrome. Pediatrics. 1988; 81: 849-856.
  88. Ulinski T., Leroy S., Dubrel M. et al. High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr. Nephrol. 2008; 23: 1107-1113.
  89. Aoun B., Wannous H., Azema С. et al. Polysaccharide pneumococcal vaccination of nephrotic children at disease onset-long-term data. Pediatr. Nephrol. 2010; 25: 1773-1774.
  90. The Australian immunisation handbook. Australian Government Department of Health and Ageing, Office of Health Protection: Woden, ACT, 2008.
  91. American Academy of Pediatrics. Sectioni: Active and passive immunization. In: Pickering L.K., Baker C.J., Long S.S., McMillan J.A. (eds). Red Book: 2006 Report of the Committee on Infectious Diseases, 27th edn. Elk Grove Village, IL, 2006; 1-103.
  92. Trachtman H., Fine R., Friedman A. et al. Quality of life in children with focal segmental glomerulosclerosis: baseline findings. Report of the FSGS clinical trial (CT) (abstract). J. Am. Soc. Nephrol. 2009; 20: 147A.
  93. Kerlin B.A., Blatt N.B., Fuh В. et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J. Pediatr. 2009; 155: 105-110.
  94. Soeiro E.M., Koch V.H., Fujimura M.D. et al. Influence of nephrotic state on the infectious profile in childhood idiopathic nephrotic syndrome. Rev. Hosp. Clin. Fac. Med. Sao. Paulo. 2004; 59: 273-278.
  95. Uncu N., Bulbul M., Yildiz N. et al. Primary peritonitis in children with nephrotic syndrome: results of a 5-year multicenter study. Eur. J. Pediatr. 2010; 169: 73-76.
  96. USRDS 2003. Annual data report: Atlas of end-stage renal disease in the United States. US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2003.
  97. Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet. 1974; 2: 423-427.
  98. Tarshish P., Tobin J.N., Bernstein J. et al. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr. Nephrol. 1996; 10: 590-593.
  99. Gipson D.S., Massengill S.F., Yao L. et al. Management of childhood onset nephrotic syndrome. Pediatrics. 2009; 124: 747-757.
  100. Abrantes M.M., Cardoso L.S., Lima E.M. et al. Predictive factors of chronic kidney disease in primary focal segmental glomerulosclerosis. Pediatr. Nephrol. 2006; 21: 1003-1012.
  101. Chitalia V.C., Wells J.E., Robson R.A. et al. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int. 1999; 56: 2236-2242.
  102. Cosio F.G., Hernandez R.A. Favorable prognostic significance of raised serum C3 concentration in patients with idiopathic focal glomerulosclerosis. Clin. Nephrol. 1996; 45: 146-152.
  103. Troyanov S., Wall C.A., Miller J.A. et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J. Am. Soc. Nephrol. 2005; 16: 1061-1068.
  104. Hogg R.J., Furth S., Lemley K.V. et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and ddolescents: evaluation, classification, and stratification. Pediatrics. 2003; 111: 1416-1421.
  105. Chernin G., Heeringa S.F., Gbadegesin R. et al. Low prevalence of NPHS2 mutations in African American children with steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 2008; 23: 1455-1460.
  106. Karle S.M., Uetz B., Ronner V. et al. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J. Am. Soc. Nephrol. 2002; 13: 388-393.
  107. Faul C., Donnelly M., Merscher-Gomez S. et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 2008; 14: 931-938.
  108. Garin E.H., Orak J.K., Hiott K.L. et al. Cyclosporine therapy for steroid-resistant nephrotic syndrome. A controlled study. Am. J. Dis. Child. 1988; 142: 985-988.
  109. Lieberman K.V., Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J. Am. Soc. Nephrol. 1996; 7: 56-63.
  110. Ponticelli C., Rizzoni G., Edefonti A. et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993; 43: 1377-1384.
  111. Gipson D.S., Trachtman H., Kaskel F.J. et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011; 80: 868-878.
  112. Caridi G., Perfumo F., Ghiggeri G.M. NPHS2 (Podocin) mutations in nephrotic syndrome. Clinical spectrum and fine mechanisms. Pediatr. Res. 2005; 57: 54R-61R.
  113. Choudhry S., Bagga A., Hari P. et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am. J. Kidney. Dis. 2009; 53: 760-769.
  114. Winn M.P. Not all in the family: mutations of podocin in sporadic steroid-resistant nephrotic syndrome. J. Am. Soc. Nephrol. 2002; 13: 577-579.
  115. Bagga A., Mudigoudar B.D., Hari P. et al. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 2004; 19: 45-50.
  116. Li Z., Duan C., He J. et al. Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 2010; 25: 883-888.
  117. Hari P., Bagga A., Mantan M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr. 2004; 41: 993-1000.
  118. de Mello V.R., Rodrigues M.T., Mastrocinque T.H. et al. Mycophenolate mofetil in children with steroid/cyclophosphamide-resistant nephrotic syndrome. Pediatr. Nephrol. 2010; 25: 453-460.
  119. Hodson E.M., Craig J.C. Therapies for steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 2008; 23: 1391-1394.
  120. Plank C., Kalb V., Hinkes В. et al. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft fur Padiatrische Nephrologie. Pediatr. Nephrol. 2008; 23: 1483-1493.
  121. Nachman P.H., Jennette J.C., Falk R.J. Primary glomerular diseases. In: Brenner BM (ed). Brenner and Rector’s The Kidney, 8th edn. Saunders/ Elsevier: Philadelphia, PA, 2008; 987-1066.
  122. Arneil G.C., Lam C.N. Long-term assessment of steroid therapy in childhood nephrosis. Lancet. 1966; 2: 819-821.
  123. Black D.A., Rose G., Brewer D.B. Controlled trial of prednisone in adult patients with the nephrotic syndrome. Br. Med. J. 1970; 3: 421-426.
  124. Coggins C.H. Adult minimal change nephropathy: experience of the collaborative study of glomerular disease. Trans. Am. Clin. Climatol. Assoc. 1986; 97: 18-26.
  125. Huang J.J., Hsu S.C., Chen F.F. et al. Adult-onset minimal change disease among Taiwanese: clinical features, therapeutic response, and prognosis. Am. J. Nephrol. 2001; 21: 28-34.
  126. Radhakrishnan J., Appel A.S., Valeri A. et al. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am. J. Kidney Dis. 1993; 22: 135-142.
  127. Mclntyre P., Craig J.C. Prevention of serious bacterial infection in children with nephrotic syndrome. J. Paediatr. Child Health. 1998; 34: 314-317.
  128. Mahmoodi B.K., ten Kate M.K., Waanders F. et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation. 2008; 117: 224-230.
  129. Мак S.K., Short C.D., Mallick N.P. Long-term outcome of adult-onset minimal-change nephropathy. Nephrol. Dial. Transplant. 1996; 11: 2192-2201.
  130. Waldman M., Crew R.J., Valeri A. et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin. J. Am. Soc. Nephrol.2007; 2: 445-453.
  131. Korbet S.M., Schwartz M.M., Lewis E.J. Minimal-change glomerulopathy of adulthood. Am. J. Nephrol. 1988; 8: 291-297.
  132. Nolasco F., Cameron J.S., Heywood E.F. et al. Adult-onset minimal change nephrotic syndrome: a long-term follow-up. Kidney Int. 1986; 29: 1215-1223.
  133. Tse К.С., Lam M.F., Yip P.S. et al. Idiopathic minimal change nephrotic syndrome in older adults: steroid responsiveness and pattern of relapses. Nephrol. Dial. Transplant. 2003; 18: 1316-1320.
  134. Appel G.B., Radhakrishnan J., d’Agati V. Secondary glomerular diseases. In: Brenner B.M. (ed). Brenner and Rector’s The Kidney, 8th edn. Saunders/ Elsevier: Philadelphia, PA, 2008; 1067-1146.
  135. Hodson E.M., Willis N.S., Craig J.C. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst. Rev. 2007: CD001533.
  136. Palmer S.C., Nand K., Strippoli G.F. Interventions for minimal change disease in adults with nephrotic syndrome. Cochrane Database Syst. Rev. 2008: CD001537.
  137. Al-Khader A.A., Lien J.W., Aber G.M. Cyclophosphamide alone in the treatment of adult patients with minimal change glomerulonephritis. Clin. Nephrol. 1979; 11: 26-30.
  138. Uldall P.R., Feest T.G., Morley A.R. et al. Cyclophosphamide therapy in adults with minimal-change nephrotic syndrome. Lancet. 1972; 1: 1250-1253.
  139. Matsumoto H., Nakao T., Okada T. et al. Favorable outcome of low-dose cyclosporine after pulse methylprednisolone in Japanese adult minimal-change nephrotic syndrome. Intern. Med. 2004; 43: 668-673.
  140. Li X., Li H., Chen J. et al. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome. Nephrol. Dial. Transplant. 2008; 23: 1919-1925.
  141. Meyrier A., Condamin M.C., Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin. Nephrol. 1991; 35 (Suppl. 1): S37-S42.
  142. Eguchi A., Takei T., Yoshida T. et al. Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. Nephrol. Dial. Transplant. 2010; 25: 124-129.
  143. Meyrier A., Niaudet P., Brodehl J. Optimal use of Sandimmun in Nephrotic Syndrome. Springer: Berlin, Germany, 1993.
  144. Meyrier A., Noel L.H., Auriche P. et al. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int. 1994; 45: 1446-1456.
  145. Choi M.J., Eustace J.A., Gimenez L.F. et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 2002; 61: 1098-1114.
  146. Fujinaga S., Ohtomo Y., Hirano D. et al. Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin. Nephrol. 2009; 72: 268-273.
  147. Siu Y.P., Tong M.K., Leung К. et al. The use of enteric-coated mycophenolate sodium in the treatment of relapsing and steroid-dependent minimal change disease. J. Nephrol. 2008; 21: 127-131.
  148. Jennette JC, Falk RJ. Adult minimal change glomerulopathy with acute renal failure. Am. J. Kidney Dis. 1990; 16: 432-437.
  149. Lechner B.L., Bockenhauer D., Iragorri S. et al. The risk of cardiovascular disease in adults who have had childhood nephrotic syndrome. Pediatr. Nephrol. 2004; 19: 744-748.
  150. Yalavarthy R., Smith M.L., Edelstein C. Acute kidney injury complicating minimal change disease: the case for careful use of diuretics and angiotensin-converting enzyme inhibitors. Nephrology (Carlton). 2007; 12: 529-531.
  151. Colquitt J.L., Kirby J., Green С. et al. The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Health Technol. Assess. 2007; 11: iii-iiv, ix-xi, 1-93.
  152. D’Agati V. Pathologic classification of focal segmental glomerulo-sclerosis. Semin. Nephrol. 2003; 23: 117-134.
  153. Braden G.L., Mulhern J.G., O’Shea M.H. et al. Changing incidence of glomerular diseases in adults. Am. J. Kidney Dis. 2000; 35: 878-883.
  154. Haas M., Meehan S.M., Karrison T.G. et al. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976 to 1979 and 1995 to 1997. Am. J. Kidney Dis. 1997; 30: 621-631.
  155. Deegens J.K., Steenbergen E.J., Wetzels J.F. Review on diagnosis and treatment of focal segmental glomerulosclerosis. Neth. J. Med. 2008; 66: 3-12.
  156. Deegens J.K., Dijkman H.B., Borm G.F. et al. Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis. Kidney Int. 2008; 74: 1568-1576.
  157. Aucella F., De Bonis P., Gatta G. et al. Molecular analysis of NPHS2 and ACTN4 genes in a series of 33 Italian patients affected by adult-onset nonfamilial focal segmental glomerulosclerosis. Nephron. Clin. Pract. 2005; 99: c31-c36.
  158. Caridi G., Bertelli R., Scolari F. et al. Podocin mutations in sporadic focal-segmental glomerulosclerosis occurring in adulthood. Kidney Int. 2003; 64: 365.
  159. Gigante M., Pontrelli P., Montemurno E. et al. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). Nephrol. Dial. Transplant. 2009; 24: 1858-1864.
  160. He N., Zahirieh A., Mei Y. et al. Recessive NPHS2 (Podocin) mutations are rare in adult-onset idiopathic focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2007; 2: 31-37.
  161. Machuca E., Hummel A., Nevo F. et al. Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant. Kidney Int. 2009; 75: 727-735.
  162. Santin S., Ars E., Rossetti S. et al. TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 2009; 24: 3089-3096.
  163. Santin S., Garcia-Maset R., Ruiz P. et al. Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. Kidney Int. 2009; 76: 1268-1276.
  164. Genovese G., Friedman D.J., Ross M.D. et al. Association of trypanolytic ApoLI variants with kidney disease in African Americans. Science 2010; 329: 841-845.
  165. Cameron J.S., Turner D.R., Ogg C.S. et al. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin. Nephrol. 1978; 10: 213-218.
  166. Korbet S.M., Schwartz M.M., Lewis E.J. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am. J. Kidney. Dis. 1994; 23: 773-783.
  167. Velosa J.A., Donadio Jr J.V., Holley K.E. Focal sclerosing glomerulonephropathy: a clinicopathologic study. Mayo. Clin. Proc. 1975; 50: 121-133.
  168. Banfi G., Moriggi M., Sabadini E. et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin. Nephrol. 1991; 36: 53-59.
  169. Cattran D.C., Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am. J. Kidney. Dis. 1998; 32: 72-79.
  170. Korbet S.M. Treatment of primary focal segmental glomerulosclerosis. Kidney Int. 2002; 62: 2301-2310.
  171. Rydel J.J., Korbet S.M., Borok R.Z. et al. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am. J. Kidney. Dis. 1995; 25: 534-542.
  172. Goumenos D.S., Tsagalis G., El Nahas A.M. et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron. Clin. Pract. 2006; 104: c75-c82.
  173. Pei Y., Cattran D., Delmore T. et al. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am. J. Med. 1987; 82: 938-944.
  174. Stirling C.M., Mathieson P., Boulton-Jones J.M. et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM. 2005; 98: 443-449.
  175. Wehrmann M., Bohle A., Held H. et al. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin. Nephrol. 1990; 33: 115-122.
  176. Caridi G., Gigante M., Ravani P. et al. Clinical features and long-term outcome of nephrotic syndrome associated with heterozygous NPHS1 and NPHS2 mutations. Clin. J. Am. Soc. Nephrol. 2009; 4: 1065-1072.
  177. Beaufils H., Alphonse J.C., Guedon J. et al. Focal glomerulosclerosis: natural history and treatment. A report of 70 cases. Nephron. 1978; 21: 75-85.
  178. Praga M., Martinez M.A., Andres A. et al. Acute renal failure and tubular dysfunction associated with minimal change nephrotic syndrome. Nephrol. Dial. Transplant. 1989; 4: 914-916.
  179. Deegens J.K., Assmann K.J., Steenbergen E.J. et al. Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? Neth. J. Med. 2005; 63: 393-398.
  180. Gupta K., Iskandar S.S., Daeihagh P. et al. Distribution of pathologic findings in individuals with nephrotic proteinuria according to serum albumin. Nephrol. Dial. Transplant. 2008; 23: 1595-1599.
  181. Duncan N., Dhaygude A., Owen J. et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol. Dial. Transplant. 2004; 19: 3062-3067.
  182. Cattran D.C., Alexopoulos E., Heering P. et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int. 2007; 72: 1429-1447.
  183. Shiiki H., Nishino T., Uyama H. et al. Clinical and morphological predictors of renal outcome in adult patients with focal and segmental glomerulosclerosis (FSGS). Clin. Nephrol. 1996; 46: 362-368.
  184. Braun N., Schmutzler F., Lange С. et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database of Systematic Reviews. 2008: CD003233.
  185. Cattran D.C., Appel G.B., Hebert L.A. et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999; 56: 2220-2226.
  186. Ghiggeri G.M., Catarsi P., Scolari F. et al. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin. Ther. 2004; 26: 1411-1418.
  187. Heering P., Braun N., Mullejans R. et al. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am. J. Kidney. Dis. 2004; 43: 10-18.
  188. Ittel T.H., Clasen W., Fuhs M. et al. Long-term ciclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis. Clin. Nephrol. 1995; 44: 156-162.
  189. Melocoton T.L., Kamil E.S., Cohen A.H. et al. Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. Am. J. Kidney. Dis. 1991; 18: 583-588.
  190. Segarra A., Vila J., Pou L. et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol. Dial. Transplant. 2002; 17: 655-662.
  191. Abe S., Amagasaki Y., Konishi К. et al. Idiopathic membranous glomerulonephritis: aspects of geographical differences. J. Clin. Pathol. 1986; 39: 1193-1198.
  192. Cahen R., Francois B., Trolliet P. et al. Aetiology of membranous glomerulonephritis: a prospective study of 82 adult patients. Nephrol. Dial. Transplant. 1989; 4: 172-180.
  193. Schwartz M.M. Membranous glomerulonephritis. In: Jennette J.C., Olson J.L., Schwartz M.M (eds). Heptinstall’s Pathology of the Kidney, 6th edn, vol. 1. Lippincott Williams & Wilkins: Philadelphia, PA, 2007; 205-251.
  194. Kuroki A., Shibata T., Honda H. et al. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern. Med. 2002; 41: 936-942.
  195. Ohtani H., Wakui H., Komatsuda A. et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol. Dial. Transplant. 2004; 19: 574-579.
  196. Zeng C.H., Chen H.M., Wang R.S. et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am. J. Kidney. Dis. 2008; 52: 691-698.
  197. Honkanen E. Survival in idiopathic membranous glomerulonephritis. Clin. Nephrol. 1986; 25: 122-128.
  198. Ehrenreich T., Porush J.G., Churg J. et al. Treatment of idiopathic membranous nephropathy. N. Engl. J. Med. 1976; 295: 741-746.
  199. Lefaucheur C., Stengel B., Nochy D. et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 2006; 70: 1510-1517.
  200. Beck Jr L.H., Bonegio R.G., Lambeau G. et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 2009; 361: 11-21.
  201. Glassock R.J. Secondary membranous glomerulonephritis. Nephrol. Dial. Transplant. 1992; 7 (Suppl. 1): 64-71.
  202. Gluck M.C., Gallo G., Lowenstein J. et al. Membranous glomerulonephritis. Evolution of clinical and pathologic features. Ann. Intern. Med. 1973; 78: 1-12.
  203. Burstein D.M., Korbet S.M., Schwartz M.M. Membranous glomerulonephritis and malignancy. Am. J. Kidney. Dis. 1993; 22: 5-10.
  204. Jha V., Ganguli A., Saha T.K. et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 2007; 18: 1899-1904.
  205. Passerini P., Ponticelli C. Membranous nephropathy. In: Ponticelli C., Glassock R. (eds). Treatment of Primary Glomerulonephritis, 2nd edn. Oxford University Press: Oxford, UK, 2009; 261-312.
  206. Glassock R.J. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003; 23: 324-332.
  207. Cameron J.S. Membranous nephropathy and its treatment. Nephrol. Dial. Transplant. 1992; 7 (Suppl. 1): 72-79.
  208. Cattran D.C. Idiopathic membranous glomerulonephritis. Kidney Int. 2001; 59: 1983-1994.
  209. Donadio Jr J.V., Torres V.E., Velosa J.A. et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int. 1988; 33: 708-715.
  210. Erwin D.T., Donadio Jr J.V., Holley K.E. The clinical course of idiopathic membranous nephropathy. Mayo. Clin. Proc. 1973; 48: 697-712.
  211. Hopper Jr J., Trew P.A., Biava C.G. Membranous nephropathy: its relative benignity in women. Nephron. 1981; 29: 18-24.
  212. Murphy B.F., Fairley K.F., Kincaid-Smith P.S. Idiopathic membranous glomerulonephritis: long-term follow-up in 139 cases. Clin. Nephrol. 1988; 30: 175-181.
  213. Row P.G., Cameron J.S., Turner D.R. et al. Membranous nephropathy. Long-term follow-up and association with neoplasia. Q. J. Med. 1975; 44: 207-239.
  214. Schieppati A., Mosconi L., Perna A. et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N. Engl. J. Med. 1993; 329: 85-89.
  215. Polanco N., Gutierrez E., Covarsi A. et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 2010; 21: 697-704.
  216. Cattran D. Management of membranous nephropathy: when and what for treatment. J. Am. Soc. Nephrol. 2005; 16: 1188-1194.
  217. Cattran D.C., Reich H.N., Beanlands H.J. et al. The impact of sex in primary glomerulonephritis. Nephrol. Dial. Transplant. 2008; 23: 2247-2253.
  218. Pei Y., Cattran D., Greenwood С. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int. 1992; 42: 960-966.
  219. Cattran D.C., Pei Y., Greenwood C.M. et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int. 1997; 51: 901-907.
  220. Fervenza F.C., Sethi S., Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin. J. Am. Soc. Nephrol.2008; 3: 905-919.
  221. Laluck Jr B.J., Cattran D.C. Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am. J. Kidney. Dis. 1999; 33: 1026-1032.
  222. Troyanov S., Wall C.A., Miller J.A. et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2004; 66: 1199-1205.
  223. Kosmadakis G., Filiopoulos V., Georgoulias С. et al. Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. Scand. J. Urol. Nephrol. 2010; 44: 251-256.
  224. Reichert L.J., Koene R.A., Wetzels J.F. Urinary excretion of beta-2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 1995; 6: 1666-1669.
  225. Reichert L.J., Koene R.A., Wetzels J.F. Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy. Clin. Nephrol. 1997; 48: 79-84.
  226. Donadio Jr J.V., Holley K.E., Anderson C.F. et al. Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int. 1974; 6: 431-439.
  227. Murphy B.F., McDonald I., Fairley K.F. et al. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin. Nephrol. 1992; 37: 229-234.
  228. Shearman J.D., Yin Z.G., Aarons I. et al. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy. Clin. Nephrol. 1988; 30: 320-329.
  229. Ponticelli C., Zucchelli P., Imbasciati E. et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N. Engl. J. Med. 1984; 310: 946-950.
  230. Falk R.J., Hogan S.L., Muller K.E. et al. Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann. Intern. Med. 1992; 116: 438-445.
  231. McQuarrie E.P., Stirling C.M., Geddes C.C. Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy. Nephrol. Dial. Transplant. 2012; 27: 235-242.
  232. Ponticelli C., Zucchelli P., Passerini P. et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N. Engl. J. Med. 1989; 320: 8-13.
  233. Ponticelli C., Zucchelli P., Passerini P. et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995; 48: 1600-1604.
  234. Ponticelli C., Zucchelli P., Passerini P. et al. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N. Engl. J. Med. 1992; 327: 599-603.
  235. Ponticelli C., Altieri P., Scolari F. et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 1998; 9: 444-450.
  236. Hogan S.L., Muller K.E., Jennette J.C. et al. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am. J. Kidney. Dis. 1995; 25: 862-875.
  237. Imperiale T.F., Goldfarb S., Berns J.S. Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials. J. Am. Soc. Nephrol. 1995; 5: 1553-1558.
  238. Jindal K., West M., Bear R. et al. Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am. J. Kidney. Dis. 1992; 19: 61-67.
  239. Perna A., Schieppati A., Zamora J. et al. Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am. J. Kidney. Dis. 2004; 44: 385-401.
  240. West M.L., Jindal K.K., Bear R.A. et al. A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis. Kidney Int. 1987; 32: 579-584.
  241. Hofstra J.M., Branten A.J., Wirtz J. et al. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol. Dial. Transplant. 2010; 25:129-136.
  242. Branten A.J., Reichert L.J., Koene R.A. et al. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM 1998; 91: 359-366.
  243. du Buf-Vereijken P.W., Branten A.J., Wetzels J.F. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol. Dial. Transplant. 2004; 19: 1142-1148.
  244. Controlled trial of azathioprine and prednisone in chronic renal disease. Report by Medical Research Council Working Party. Br. Med. J. 1971; 2: 239-241.
  245. Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis. Can. Med. Assoc. J. 1976; 115: 1209-1210.
  246. Lagrue G., Bernard D., Bariety J. et al. Treatment with chlorambucil and azathioprine in primary glomerulonephritis. Results of a ‘controlled’ study. J. Urol. Nephrol. (Paris). 1975; 81: 655-672.
  247. Ambalavanan S., Fauvel J.P., Sibley R.K. et al. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J. Am. Soc. Nephrol. 1996; 7: 290-298.
  248. Guasch A., Suranyi M., Newton L. et al. Short-term responsiveness of membranous glomerulopathy to cyclosporine. Am. J. Kidney. Dis. 1992; 20: 472-481.
  249. Cattran D.C., Appel G.B., Hebert L.A. et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 2001; 59: 1484-1490.
  250. Alexopoulos E., Papagianni A., Tsamelashvili M. et al. Induction and long-term treatment with cyclosporin A in membranous glomerulonephritis with the nephrotic syndrome (abstract). J. Am. Soc. Nephrol. 2005; 16: 780A.
  251. Cattran D.C., Greenwood C., Ritchie S. et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int. 1995; 47: 1130-1135.
  252. DeSanto N.G., Capodicasa G., Giordano С. Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporin. Am. J. Nephrol. 1987; 7: 74-76.
  253. Rostoker G., Belghiti D., Ben Maadi A. et al. Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy. Nephron 1993; 63: 335-341.
  254. Praga M., Barrio V., Juarez G.F. et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007; 71: 924-930.
  255. Bruns F.J., Adler S., Fraley D.S. et al. Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann. Intern. Med. 1991; 114: 725-730.
  256. Mathieson P.W., Turner A.N., Maidment C.G. et al. Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet. 1988; 2: 869-872.
  257. Torres A., Dominguez-Gil B., Carreno A. et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int. 2002; 61: 219-227.
  258. Warwick G.L., Geddes C.G,. Boulton-Jones J.M. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. Q. J. Med. 1994; 87: 223-229.
  259. Chen M., Li H., Li X.Y. et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am. J. Med. Sci. 2010; 339: 233-238.
  260. A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. N. Engl. J. Med. 1979; 301: 1301-1306.
  261. Cattran D.C., Delmore T., Roscoe J. et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N. Engl. J. Med. 1989; 320: 210-215.
  262. Shiiki H., Saito T., Nishitani Y. et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004; 65: 1400-1407.
  263. Branten A.J., du Buf-Vereijken P.W., Vervloet M. et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am. J. Kidney. Dis. 2007; 50: 248-256.
  264. Chan T.M., Lin A.W., Tang S.C. et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton). 2007; 12: 576-581.
  265. 264a. Senthil Nayagam L., Ganguli A., Rathi M. et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol. Dial. Transplant. 2008; 23: 1926-1930.
  266. Dussol B., Morange S., Burtey S. et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am. J. Kidney. Dis. 2008; 52: 699-705.
  267. Remuzzi G., Chiurchiu C., Abbate M. et al. Rituximab for idiopathic membranous nephropathy. Lancet. 2002; 360: 923-924.
  268. Ruggenenti P., Chiurchiu C., Brusegan V. et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J. Am. Soc. Nephrol. 2003; 14: 1851-1857.
  269. Ruggenenti P., Chiurchiu C., Abbate M. et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin. J. Am. Soc. Nephrol. 2006; 1: 738-748.
  270. Fervenza F.C., Cosio F.G., Erickson S.B. et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008; 73: 117-125.
  271. Cravedi P., Ruggenenti P., Sghirlanzoni M.C. et al. Titrating rituximab to circulating В cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 2007; 2: 932-937.
  272. Fervenza F.C., Abraham R.S., Erickson S.B. et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin. J. Am. Soc. Nephrol. 2010; 5: 2188-2198.
  273. Berg A.L., Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol. Dial. Transplant. 2004; 19: 1305-1307.
  274. Berg A.L., Nilsson-Ehle P., Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 1999; 56: 1534-1543.
  275. Ponticelli C., Passerini P., Salvadori M. et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am. J. Kidney. Dis. 2006; 47: 233-240.
  276. Ahmed S., Rahman M., Alam M.R. et al. Methyl prednisolone plus chlorambucil as compared with prednisolone alone for the treatment of idiopathic membranous nephropathy. A preliminary study. Bangladesh Renal J. 1994; 13: 51-54.
  277. Reichert L.J., Huysmans F.T., Assmann К. et al. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann. Intern. Med. 1994; 121: 328-333.
  278. Bomback A.S., Derebail V.K., McGregor J.G. et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin. J. Am. Soc. Nephrol. 2009; 4: 734-744.
  279. Nasr S.H., Said S.M., Valeri A.M. et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin. J. Am. Soc. Nephrol. 2009; 4: 299-308.
  280. Troxell M.L., Saxena A.B., Kambham N. Concurrent anti-glomerular basement membrane disease and membranous glomerulonephritis: a case report and literature review. Clin. Nephrol. 2006; 66: 120-127.
  281. Waldman M., Austin III H.A. Controversies in the treatment of idiopathic membranous nephropathy. Nat. Rev. Nephrol. 2009; 5: 469-479.
  282. Ponticelli C., Passerini P., Altieri P. et al. Remissions and relapses in idiopathic membranous nephropathy. Nephrol. Dial. Transplant. 1992; 7 (Suppl. 1): 85-90.
  283. Suki W.N., Trimarchi H., Frommer J.P. Relapsing membranous nephropathy. Response to therapy of relapses compared to that of the original disease. Am. J. Nephrol. 1999; 19: 474-479.
  284. du Buf-Vereijken P.W., Wetzels J.F. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrol. Dial. Transplant. 2004; 19: 2036-2043.
  285. Faurschou M., Sorensen I.J., Mellemkjaer L. et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J. Rheumatol. 2008; 35: 100-105.
  286. Segarra A., Praga M., Ramos N. et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin. J. Am. Soc. Nephrol. 2009; 4: 1083-1088.
  287. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978; 13: 159-165.
  288. USRDS 2008. Annual data report: Atlas of chronic kidney disease. Atlas of end-stage renal disease. US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, 2008.
  289. Menon S., Valentini R.P. Membranous nephropathy in children: clinical presentation and therapeutic approach. Pediatr. Nephrol. 2010; 25: 1419-1428.
  290. Makker S.P. Treatment of membranous nephropathy in children. Semin Nephrol. 2003; 23: 379-385.
  291. Watson A.R., Ranee C.P., Bain J. Long term effects of cyclophosphamide on testicular function. Br. Med. J. (Clin. Res. Ed.) 1985; 291: 1457-1460.
  292. Habib R., Kleinknecht C., Gubler M.C. Extramembranous glomerulonephritis in children: report of 50 cases. J. Pediatr. 1973; 82: 754-766.
  293. Olbing H., Greifer I., Bennett B.P. et al. Idiopathic membranous nephropathy in children. Kidney Int. 1973; 3: 381-390.
  294. Chan W.C., Tsao Y.C. Diffuse membranous glomerulonephritis in children. J Clin. Pathol. 1966; 19: 464-469.
  295. Trainin E.B., Boichis H., Spitzer A. et al. Idiopathic membranous nephropathy. Clinical course in children. N. Y. State. J. Med. 1976; 76: 357-360.
  296. Latham P., Poucell S., Koresaar A. et al. Idiopathic membranous glomerulopathy in Canadian children: a clinicopathologic study. J. Pediatr. 1982; 101: 682-685.
  297. Ramirez F., Brouhard B.H., Travis L.B. et al. Idiopathic membranous nephropathy in children. J. Pediatr. 1982; 101: 677-681.
  298. Tsukahara H., Takahashi Y., Yoshimoto M. et al. Clinical course and outcome of idiopathic membranous nephropathy in Japanese children. Pediatr. Nephrol. 1993; 7: 387-391.
  299. Lee B.H., Cho H.Y., Kang H.G. et al. Idiopathic membranous nephropathy in children. Pediatr. Nephrol. 2006; 21: 1707-1715.
  300. Chen A., Frank R., Vento S. et al. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. ВМС Nephrol. 2007; 8: 11.
  301. Valentini R.P., Mattoo T.K., Kapur G. et al. Membranous glomerulonephritis: treatment response and outcome in children. Pediatr. Nephrol. 2009; 24: 301-308.
  302. Bellomo R., Atkins R.C. Membranous nephropathy and thrombo-embolism: is prophylactic anticoagulation warranted? Nephron. 1993; 63: 249-254.
  303. Glassock R.J. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J. Am. Soc. Nephrol. 2007; 18: 2221-2225.
  304. Sarasin F.P., Schifferli J.A. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int. 1994; 45: 578-585.
  305. Glassock R.J. Membranoproliferative glomerulonephritis. In: Molony D.A., Craig J.C. (eds). Evidence-based Nephrology, 1st edn. John Wiley & Sons: Hoboken, N.J., 2008; 183-195.
  306. Glassock R.J. Membranoproliferative glomerulonephritis. In: Ponticelli C., Glassock R. (eds). Treatment of Primary Glomerulonephritis, 2nd edn. Oxford University Press: Oxford, UK, 2009; 375-398.
  307. West C.D., McAdams A.J., McConville J.M. et al. Hypocomplementemic and normocomplementemic persistent (chronic) glomerulonephritis; clinical and pathologic characteristics. J. Pediatr. 1965; 67: 1089-1112.
  308. Fakhouri F., Fremeaux-Bacchi V., Noel L.H. et al. C3 glomerulopathy: a new classification. Nat. Rev. Nephrol. 2010; 6: 494-499.
  309. Sethi S., Fervenza F.C. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin. Nephrol. 2011; 31: 341-348.
  310. Appel G.B., Cook H.T., Hageman G. et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J. Am. Soc. Nephrol. 2005; 16: 1392-1403.
  311. Holley K.E., Donadio J.V. Membranoproliferative glomerulonephritis. In: Tisher CC, Brenner BM (eds). Renal. Pathology (with Clinical and Functional Correlations), 2nd edn. JB Lippincott and Co: Philadelphia, PA, 1994; 294-329.
  312. Servais A., Fremeaux-Bacchi V., Salomon R. et al. Mutations in complement regulatory genes, Factor H, I and CD46 and C3 nephritic factor predispose to membranoproliferative glomerulonephritis with isolated mesangial C3 deposition (abstract). J. Am. Soc. Nephrol. 2005; 16: 51A.
  313. Schwertz R., Rother U., Anders D. et al. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr. Allergy. Immunol. 2001; 12: 166-172.
  314. Smith R.J., Alexander J., Barlow P.N. et al. New approaches to the treatment of dense deposit disease. J. Am. Soc. Nephrol. 2007; 18: 2447-2456.
  315. Asinobi А.О., Gbadegesin R.A., Adeyemo A.A. et al. The predominance of membranoproliferative glomerulonephritis in childhood nephrotic syndrome in Ibadan, Nigeria. West Afr. J. Med. 1999; 18: 203-206.
  316. Donadio Jr J.V., Anderson C.F., Mitchell III J.C. et al. Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N. Engl. J. Med. 1984; 310: 1421-1426.
  317. Donadio Jr J.V., Offord K.P. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am. J. Kidney. Dis. 1989; 14: 445-451.
  318. Emre S., Sirin A., Alpay H. et al. Pulse methylprednisolone therapy in children with membranoproliferative glomerulonephritis. Acta. Paediatr. Jpn. 1995; 37: 626-629.
  319. Zauner I., Bohler J., Braun N. et al. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multicentre prospective clinical trial. Collaborative Glomerulonephritis Therapy Study Group (CGTS). Nephrol. Dial. Transplant. 1994; 9: 619-622.
  320. McEnery P.T. Membranoproliferative glomerulonephritis: the Cincinnati experience-cumulative renal survival from 1957 to 1989. J. Pediatr. 1990; 116: S109-S114.
  321. McEnery P.T., McAdams A.J., West C.D. The effect of prednisone in a high-dose, alternate-day regimen on the natural history of idiopathic membranoproliferative glomerulonephritis. Medicine (Baltimore). 1985; 64: 401-424.
  322. Tarshish P., Bernstein J., Tobin J.N. et al. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone-a report of the International Study of Kidney Disease in Children. Pediatr. Nephrol. 1992; 6: 123-130.
  323. Warady B.A., Guggenheim S.J., Sedman A. et al. Prednisone therapy of membranoproliferative glomerulonephritis in children. J. Pediatr. 1985; 107: 702-707.
  324. Bergstein J.M., Andreoli S.P. Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy. Pediatr. Nephrol. 1995; 9: 268-271.
  325. Cattran D.C., Cardella C.J., Roscoe J.M. et al. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int. 1985; 27: 436-441.
  326. Chapman S.J., Cameron J.S., Chantler С. et al. Treatment of mesangiocapillary glomerulonephritis in children with combined immunosuppression and anticoagulation. Arch. Dis. Child. 1980; 55: 446-451.
  327. Faedda R., Satta A., Tanda F. et al. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron. 1994; 67: 59-65.
  328. Jones G., Juszczak M., Kingdon E. et al. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol. Dial. Transplant. 2004; 19: 3160-3164.
  329. Levin A. Management of membranoproliferative glomerulonephritis: evidence-based recommendations. Kidney Int. Suppl. 1999; 70: S41-S46.
  330. Tiller D., Clarkson A.R., Mathew T. A prospective randomized trial fo the use of cyclophosphamide, dipyridamole and warfarin in membranous and membranoproliferative glomerulonephritis. In: Robinson R., Glassock R., Tisher C.C., Andreoli T. et al. (eds). Proceedings of the 8th International Congress of Nephrology. Karger: Basel, Switzerland, 1981; 345-351.
  331. Montseny J.J., Meyrier A., Kleinknecht D. et al. The current spectrum of infectious glomerulonephritis. Experience with 76 patients and review of the literature. Medicine (Baltimore). 1995; 74: 63-73.
  332. Moroni G., Pozzi C., Quaglini S. et al. Long-term prognosis of diffuse proliferative glomerulonephritis associated with infection in adults. Nephrol. Dial. Transplant. 2002; 17: 1204-1211.
  333. Nasr S.H., Markowitz G.S., Stokes M.B. et al. Acute postinfectious glomerulonephritis in the modern era: experience with 86 adults and review of the literature. Medicine (Baltimore). 2008; 87: 21-32.
  334. Moroni G., Ponticelli С. Acute post-infectious glomerulonephritis. In: Ponticelli C., Glassock R. (eds). Treatment of Primary Glomerulonephritis, 2nd edn. Oxford University Press: Oxford, UK, 2009; 153-177.
  335. Rodriguez-lturbe B., Musser J.M. The current state of poststreptococcal glomerulonephritis. J. Am. Soc. Nephrol. 2008; 19: 1855-1864.
  336. Batsford S.R., Mezzano S., Mihatsch M. et al. Is the nephritogenic antigen in post-streptococcal glomerulonephritis pyrogenic exotoxin В (SPE B) or GAPDH? Kidney Int. 2005; 68: 1120-1129.
  337. Yoshizawa N., Yamakami K., Fujino M. et al. Nephritis-associated plasmin receptor and acute poststreptococcal glomerulonephritis: characterization of the antigen and associated immune response. J. Am. Soc. Nephrol. 2004; 15: 1785-1793.
  338. Baldwin D.S. Poststreptococcal glomerulonephritis. A progressive disease? Am. J. Med. 1977; 62: 1-11.
  339. Habib G., Hoen B., Tornos P. et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur. Heart. J. 2009; 30: 2369-2413.
  340. Hoen B., Alia F., Selton-Suty С. et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA. 2002; 288: 75-81.
  341. Koya D., Shibuya K., Kikkawa R. et al. Successful recovery of infective endocarditis-induced rapidly progressive glomerulonephritis by steroid therapy combined with antibiotics: a case report. ВМС Nephrol. 2004; 5: 18.
  342. Iwata Y., Ohta S., Kawai К. et al. Shunt nephritis with positive titers for ANCA specific for proteinase 3. Am. J. Kidney. Dis. 2004; 43: el1-el6.
  343. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis С in chronic kidney disease. Kidney Int. Suppl. 2008: S1-S99.
  344. Alter M.J. Epidemiology of hepatitis С virus infection. World J. Gastroenterol. 2007; 13: 2436-2441.
  345. Poynard T., Yuen M.F., Ratziu V. et al. Viral hepatitis С. Lancet. 2003; 362: 2095-2100.
  346. Williams R. Global challenges in liver disease. Hepatology. 2006; 44: 521-526.
  347. Perico N., Cattaneo D., Bikbov В. et al. Hepatitis С infection and chronic renal diseases. Clin. J. Am. Soc. Nephrol. 2009; 4: 207-220.
  348. Johnson R.J., Gretch D.R., Yamabe H. et al. Membranoproliferative glomerulonephritis associated with hepatitis С virus infection. N. Engl. J. Med. 1993; 328: 465-470.
  349. Meyers C.M., Seeff L.B., Stehman-Breen C.O. et al. Hepatitis С and renal disease: an update. Am. J. Kidney. Dis. 2003; 42: 631-657.
  350. Roccatello D., Fornasieri A., Giachino О. et al. Multicenter study on hepatitis С virus-related cryoglobulinemic glomerulonephritis. Am. J. Kidney Dis. 2007; 49: 69-82.
  351. D’Amico G. Renal involvement in hepatitis С infection: cryoglobulinemic glomerulonephritis. Kidney Int. 1998; 54: 650-671.
  352. Arase Y., Ikeda K., Murashima N. et al. Glomerulonephritis in autopsy cases with hepatitis С virus infection. Intern. Med. 1998; 37: 836-840.
  353. Kamar N., Izopet J., Alric L. et al. Hepatitis С virus-related kidney disease: an overview. Clin. Nephrol. 2008; 69: 149-160.
  354. Markowitz G.S., Cheng J.T., Colvin R.B. et al. Hepatitis С viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J. Am. Soc. Nephrol. 1998; 9: 2244-2252.
  355. Sabry A., A EA, Sheashaa H. et al. HCV associated glomerulopathy in Egyptian patients: clinicopathological analysis. Virology. 2005; 334: 10-16.
  356. Ghany M.G., Strader D.B., Thomas D.L. et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49: 1335-1374.
  357. Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis С virus infection. N. Engl. J. Med. 2002; 347: 975-982.
  358. Hadziyannis S.J., Sette Jr H., Morgan T.R. et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 346-355.
  359. Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358: 958-965.
  360. Johnson R.J., Gretch D.R., Couser W.G. et al. Hepatitis С virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int. 1994; 46: 1700-1704.
  361. Misiani R., Bellavita P., Fenili D. et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis С virus. N. Engl. J. Med. 1994; 330: 751-756.
  362. Cresta P., Musset L., Cacoub P. et al. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis С virus. Gut. 1999; 45: 122-128.
  363. Komatsuda A., Imai H., Wakui H. et al. Clinicopathological analysis and therapy in hepatitis С virus-associated nephropathy. Intern Med. 1996; 35: 529-533.
  364. Mazzaro C., Panarello G., Carniello S. et al. Interferon versus steroids in patients with hepatitis С virus-associated cryoglobulinaemic glomerulonephritis. Dig. Liver. Dis. 2000; 32: 708-715.
  365. Cid M.C., Hernandez-Rodriguez J., Robert J. et al. Interferon-alpha may exacerbate cryoblobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity. Arthritis. Rheum. 1999; 42: 1051-1055.
  366. Suzuki T., Yonemura K., Miyaji T. et al. Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis С virus-associated membranoproliferative glomerulonephritis. Intern. Med. 2001; 40: 708-712.
  367. Garini G., Allegri L., Lannuzzella F. et al. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Ada. Biomed. 2007; 78: 51-59.
  368. Bruchfeld A., Lindahl K., Stahle L. et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol. Dial. Transplant. 2003; 18: 1573-1580.
  369. Garini G., Allegri L., Carnevali L. et al. Interferon-alpha in combination with ribavirin as initial treatment for hepatitis С virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am. J. Kidney Dis. 2001; 38: E35.
  370. Rossi P., Bertani T., Baio P. et al. Hepatitis С virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int. 2003; 63: 2236-2241.
  371. Sabry A.A., Sobh M.A., Sheaashaa H.A. et al. Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol. Dial. Transplant. 2002; 17: 1924-1930.
  372. Alric L., Plaisier E., Thebault S. et al. Influence of antiviral therapy in hepatitis С virus-associated cryoglobulinemic MPGN. Am. J. Kidney. Dis. 2004; 43: 617-623.
  373. Cacoub P., Saadoun D., Limal N. et al. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis С virus-related systemic vasculitis. Arthritis. Rheum. 2005; 52: 911-915.
  374. Mazzaro C., Zorat F., Caizzi M. et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis С virus-associated mixed cryoglobulinemia: a pilot study. J. Hepatol. 2005; 42: 632-638.
  375. Saadoun D., Resche-Rigon M., Thibault V. et al. Antiviral therapy for hepatitis С virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis. Rheum. 2006; 54: 3696-3706.
  376. Fabrizi F., Bruchfeld A., Mangano S. et al. Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. Int. J. Artif. Organs. 2007; 30: 212-219.
  377. Charles E.D., Dustin L.B. Hepatitis С virus-induced cryoglobulinemia. Kidney Int. 2009; 76: 818-824.
  378. Koziolek M.J., Scheel A., Bramlage С. et al. Effective treatment of hepatitis C-associated immune-complex nephritis with cryoprecipitate apheresis and antiviral therapy. Clin. Nephrol. 2007; 67: 245-249.
  379. Ahmed M.S., Wong C.F. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? J. Nephrol. 2007; 20: 350-356.
  380. Cacoub P., Delluc A., Saadoun D. et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann. Rheum. Dis. 2008; 67: 283-287.
  381. Sansonno D., De Re V., Lauletta G. et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003; 101: 3818-3826.
  382. Saadoun D., Resche-Rigon M., Sene D. et al. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis С virus-associated cryoglobulinaemia vasculitis. Ann. Rheum. Dis. 2008; 67: 1431-1436.
  383. Garini G., Allegri L., Carnevali M.L. et al. Successful treatment of severe/ active cryoglobulinaemic membranoproliferative glomerulonephritis associated with hepatitis С virus infection by means of the sequential administration of immunosuppressive and antiviral agents. Nephrol. Dial. Transplant. 2006; 21: 3333-3334.
  384. lannuzzella F., Vaglio A., Garini G. Management of hepatitis С virus-related mixed cryoglobulinemia. Am. J. Med. 2010; 123: 400^08.
  385. Saadoun D., Resche Rigon M., Sene D. et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010; 116: 326-334; quiz 504-525.
  386. European Association for the study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-242.
  387. Sorrell M.F., Belongia E.A., Costa J. et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann. Intern. Med. 2009; 150: 104-110.
  388. Olsen S.K., Brown Jr R.S. Hepatitis В treatment: Lessons for the nephrologist. Kidney Int. 2006; 70: 1897-1904.
  389. Appel G. Viral infections and the kidney: HIV, hepatitis B, and hepatitis С.Cleve. Clin. J. Med. 2007; 74: 353-360.
  390. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology. 2009; 50: 661-662.
  391. Sepkowitz K.A. One disease, two epidemics-AIDS at 25. N. Engl. J. Med. 2006; 354: 2411-2414.
  392. Kimmel P.L., Barisoni L., Kopp J.B. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann. Intern. Med. 2003; 139: 214-226.
  393. Wyatt C.M., Klotman P.E. HIV-1 and HIV-associated nephropathy 25 years later. Clin. J. Am. Soc. Nephrol. 2007; 2 (Suppl. 1): S20-S24.
  394. Genovese G., Tonna S.J., Knob A.U. et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int. 2010; 78: 698-704.
  395. Cohen S.D., Kimmel P.L. Immune complex renal disease and human immunodeficiency virus infection. Semin. Nephrol. 2008; 28: 535-544.
  396. Szczech L.A., Gupta S.K., Habash R. et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004; 66: 1145-1152.
  397. Szczech L.A., Hoover D.R., Feldman J.G. et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin. Infect. Dis. 2004; 39: 1199-1206.
  398. El-Sadr W.M., Lundgren J.D., Neaton J.D. et al. CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 2006; 355: 2283-2296.
  399. Kalayjian R.C., Franceschini N., Gupta S.K. et al. Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS. 2008; 22: 481-487.
  400. Krawczyk C.S., Holmberg S.D., Moorman A.C. et al. Factors associated with chronic renal failure in HIV-infected ambulatory patients. AIDS. 2004; 18: 2171-2178.
  401. Peters P.J., Moore D.M., Mermin J. et al. Antiretroviral therapy improves renal function among HIV-infected Ugandans. Kidney Int. 2008; 74: 925-929.
  402. Reid A., Stohr W., Walker A.S. et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clin. Infect. Dis. 2008; 46: 1271-1281.
  403. Gupta S.K., Parker R.A., Robbins G.K. et al. The effects of highly active antiretroviral therapy on albuminuria in HIV-infected persons: results from a randomized trial. Nephrol. Dial. Transplant. 2005; 20: 2237-2242.
  404. Gupta S.K., Smurzynski M., Franceschini N. et al. The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era. Antivir. Ther. 2009; 14: 543-549.
  405. Longenecker C.T., Scherzer R., Bacchetti P. et al. HIV viremia and changes in kidney function. AIDS. 2009; 23: 1089-1096.
  406. Wyatt C.M., Morgello S., Katz-Malamed R. et al. The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int. 2009; 75: 428-434.
  407. Wyatt C.M., Winston J.A., Malvestutto C.D. et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS. 2007; 21: 2101-2103.
  408. Haas M., Kaul S., Eustace J.A. HIV-associated immune complex glomerulonephritis with «lupus-like» features: a clinicopathologic study of 14 cases. Kidney Int. 2005; 67: 1381-1390.
  409. Fine D.M., Perazella M.A., Lucas G.M. et al. Kidney biopsy in HIV: beyond HIV-associated nephropathy. Am. J. Kidney. Dis. 2008; 51: 504-514.
  410. Gerntholtz Т.Е., Goetsch S.J., Katz I. HIV-related nephropathy: a South African perspective. Kidney Int. 2006; 69: 1885-1891.
  411. Han T.M., Naicker S., Ramdial P.K. et al. A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int. 2006; 69: 2243-2250.
  412. Cohen S.D., Kimmel P.L. Renal biopsy is necessary for the diagnosis of HIV-associated renal diseases. Nat. Clin. Pract. Nephrol. 2009; 5: 22-23.
  413. Babut-Gay M.L., Echard M., Kleinknecht D. et al. Zidovudine and nephropathy with human immunodeficiency virus (HIV) infection. Ann. Intern. Med. 1989; 111: 856-857.
  414. Ifudu O., Rao T.K., Tan C.C. et al. Zidovudine is beneficial in human immunodeficiency virus associated nephropathy. Am. J. Nephrol. 1995; 15: 217-221.
  415. Kirchner J.T. Resolution of renal failure after initiation of HAART: 3 cases and a discussion of the literature. AIDS Read. 2002; 12:103-105, 110-102.
  416. Szczech L.A., Edwards L.J., Sanders L.L. et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin. Nephrol. 2002; 57: 336-341.
  417. Lucas G.M., Eustace J.A., Sozio S. et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS. 2004; 18: 541-546.
  418. Atta M.G., Gallant J.E., Rahman M.H. et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol. Dial. Transplant. 2006; 21: 2809-2813.
  419. Kalayjian R.C. The treatment of HIV-associated nephropathy. Adv. Chronic. Kidney. Dis. 2010; 17: 59-71.
  420. Eustace J.A., Nuermberger E., Choi M. et al. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 2000; 58: 1253-1260.
  421. Laradi A., Mallet A., Beaufils H. et al. HIV-associated nephropathy: outcome and prognosis factors. Groupe d’Etudes Nephrologiques d’lle de France. J. Am. Soc. Nephrol. 1998; 9: 2327-2335.
  422. Smith M.C., Austen J.L., Carey J.T. et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am. J. Med. 1996; 101: 41-48.
  423. Ingulli E., Tejani A., Fikrig S. et al. Nephrotic syndrome associated with acquired immunodeficiency syndrome in children. J. Pediatr. 1991; 119: 710-716.
  424. Yahaya I., Uthman А.О., Uthman M.M. Interventions for HIV-associated nephropathy. Cochrane Database Syst. Rev. 2009: CD007183.
  425. Elewa U., Sandri A.M., Rizza S.A. et al. Treatment of HIV-associated nephropathies. Nephron. Clin. Pract. 2011; 118: c346-c354.
  426. Novak J.E., Szczech L.A. (eds.) HIV and kidney disease. Adv. Chronic. Kidney Dis. 2010; 17: 1-111.
  427. Chitsulo L., Engels D., Montresor A. et al. The global status of schistosomiasis and its control. Ada. Trop. 2000; 77: 41-51.
  428. Chugh K.S., Harries A.D., Dahniya M.H. et al. Urinary schistosomiasis in Maiduguri, north east Nigeria. Ann. Trop. Med. Parasitol. 1986; 80: 593-599.
  429. Abdurrahman M.B., Attah B., Narayana P.T. Clinicopathological features of hepatosplenic schistosomiasis in children. Ann. Trop. Paediatr. 1981; 1: 5-11.
  430. Abu-Romeh S.H., van der Meulen J., Cozma M.C. et al. Renal diseases in Kuwait. Experience with 244 renal biopsies. Int. Urol. Nephrol. 1989; 21: 25-29.
  431. Andrade Z.A., Andrade S.G., Sadigursky M. Renal changes in patients with hepatosplenic schistosomiasis. Am. J. Trop. Med. Hyg. 1971; 20: 77-83.
  432. Chandra Shekhar K., Pathmanathan R. Schistosomiasis in Malaysia. Rev. Infect. Dis. 1987; 9: 1026-1037.
  433. Falcao H.A., Gould D.B. Immune complex nephropathy i schistosomiasis. Ann. Intern. Med. 1975; 83: 148-154.
  434. Musa A.M., Asha H.A., Veress B. Nephrotic syndrome in Sudanese patients with schistosomiasis mansoni infection. Ann. Trop. Med. Parasitol. 1980; 74: 615-618.
  435. Queiroz P.F., Brito E., Martinelli R. et al. Nephrotic syndrome in patients with Schistosoma mansoni infection. Am. J. Trop. Med. Hyg. 1973; 22: 622-628.
  436. Rocha H., Cruz T., Brito E. et al. Renal involvement in patients with hepatosplenic Schistosomiasis mansoni. Am. J. Trop. Med. Hyg. 1976; 25: 108-115.
  437. Sobh M.A., Moustafa F.E., el-Housseini F et al. Schistosomal specific nephropathy leading to end-stage renal failure. Kidney Int. 1987; 31: 1006-1011.
  438. Barsoum R.S. Schistosomal glomerulopathies. Kidney Int. 1993; 44: 1-12.
  439. Barsoum R.S., Abdel-Rahman A.Y., Francis M.R. et al. Patterns of glomerular injury associated with hepato-splenic schistosomiasis. Proceedings of the XII Egyptian Congress of Nephrology. Cairo, Egypt. 1992.
  440. Sobh M., Moustafa F., el-Arbagy A. et al. Nephropathy in asymptomatic patients with active Schistosoma mansoni infection. Int. Urol. Nephrol. 1990; 22: 37-43.
  441. Rabello A.L., Lambertucci J.R., Freire M.H. et al. Evaluation of proteinuria in an area of Brazil endemic for schistosomiasis using a single urine sample. Trans. R. Soc. Trop. Med. Hyg. 1993; 87: 187-189.
  442. Eltoum I.A., Ghalib H.W., Sualaiman S. et al. Significance of eosinophiluria in urinary schistosomiasis. A study using Hansel’s stain and electron microscopy. Am. J. Clin. Pathol. 1989; 92: 329-338.
  443. Martinelli R., Pereira L.J., Brito E. et al. Renal involvement in prolonged Salmonella bacteremia: the role of schistosomal glomerulopathy. Rev. Inst. Med. Trop. Sao. Paulo. 1992; 34: 193-198.
  444. Bassily S., Farid Z., Barsoum R.S. et al. Renal biopsy in Schistosoma-Salmonella associated nephrotic syndrome. J. Trop. Med. Hyg. 1976; 79: 256-258.
  445. Lambertucci J.R., Godoy P., Neves J. et al. Glomerulonephritis in Salmonella-Schistosoma mansoni association. Am. J. Trop. Med. Hyg. 1988; 38: 97-102.
  446. Ross A.G., Bartley P.B., Sleigh A.C. et al. Schistosomiasis. N. Engl. J. Med. 2002; 346: 1212-1220.
  447. Martinelli R., Pereira L.J., Brito E. et al. Clinical course of focal segmental glomerulosclerosis associated with hepatosplenic schistosomiasis mansoni. Nephron. 1995; 69: 131-134.
  448. Sobh M.A., Moustafa F.E., Sally S.M. et al. A prospective, randomized therapeutic trial for schistosomal specific nephropathy. Kidney Int. 1989; 36: 904-907.
  449. Abdul-Fattah M.M., Yossef S.M., Ebraheem M.E. et al. Schistosomal glomerulopathy: a putative role for commonly associated Salmonella infection. J. Egypt. Soc. Parasitol. 1995; 25: 165-173.
  450. Martinelli R., Pereira L.J., Rocha H. The influence of anti-parasitic therapy on the course of the glomerulopathy associated with Schistosomiasis mansoni. Clin. Nephrol. 1987; 27: 229-232.
  451. Sobh M.A., Moustafa F.E., Sally S.M. et al. Characterisation of kidney lesions in early schistosomal-specific nephropathy. Nephrol. Dial. Transplant. 1988; 3: 392-398.
  452. Nussenzveig I., De Brito T., Carneiro C.R. et al. Human Schistosoma mansoni-associated glomerulopathy in Brazil. Nephrol. Dial. Transplant. 2002; 17:4-7.
  453. Bariety J., Barbier M., Laigre M.C. et al. Proteinuria and loaiasis. Histologic, optic and electronic study of a case. Bull. Mem. Soc. Med. Hop. Paris. 1967; 118: 1015-1025.
  454. Chugh K.S., Singhal P.C., Tewari S.C. et al. Acute glomerulonephritis associated with filariasis. Am. J. Trop. Med. Hyg. 1978; 27: 630-631.
  455. Date A., Gunasekaran V., Kirubakaran M.G. et al. Acute eosinophilic glomerulonephritis with Bancroftian filariasis. Postgrad. Med. J. 1979; 55: 905-907.
  456. Ngu J.L., Chatelanat F., Leke R. et al. Nephropathy in Cameroon: evidence for filarial derived immune-complex pathogenesis in some cases. Clin. Nephrol. 1985; 24: 128-134.
  457. Pillay V.K., Kirch E., Kurtzman N.A. Glomerulopathy associated with filarial loiasis. JAMA. 1973; 225: 179.
  458. Pakasa N.M., Nseka N.M., Nyimi L.M. Secondary collapsing glomerulopathy associated with Loa loa filariasis. Am. J. Kidney. Dis. 1997; 30: 836-839.
  459. Ormerod A.D., Petersen J., Hussey J.K. et al. Immune complex glomerulonephritis and chronic anaerobic urinary infection-complications of filariasis. Postgrad. Med. J. 1983; 59: 730-733.
  460. Hall C.L., Stephens L., Peat D. et al. Nephrotic syndrome due to loiasis following a tropical adventure holiday: a case report and review of the literature. Clin. Nephrol. 2001; 56: 247-250.
  461. Dreyer G., Ottesen E.A., Galdino E. et al. Renal abnormalities in microfilaremic patients with Bancroftian filariasis. Am. J. Trop. Med. Hyg. 1992; 46: 745-751.
  462. Langhammer J., Birk H.W., Zahner H. Renal disease in lymphatic filariasis: evidence for tubular and glomerular disorders at various stages of the infection. Trop. Med. Int. Health. 1997; 2: 875-884.
  463. Cruel T., Arborio M., Schill H. et al. Nephropathy and filariasis from Loa loa. Apropos of 1 case of adverse reaction to a dose of ivermectin. Bull. Soc. Pathol. Exot. 1997; 90: 179-181.
  464. Ngu J.L., Adam M., Leke R. et al. Proteinuria associated with diethylcarbamazine treatment of onchocerciasis (abstract). Lancet. 1980; 315: 710.
  465. Abel L., loly V., Jeni P. et al. Apheresis in the management of loiasis with high microfilariaemia and renal disease. Br. Med. J. (Clin. Res. Ed.). 1986; 292: 24.
  466. Barsoum R.S. Malarial nephropathies. Nephrol. Dial. Transplant. 1998; 13: 1588-1597.
  467. Eiam-Ong S. Malarial nephropathy. Semin. Nephrol. 2003; 23: 21-33.
  468. Olowu W.A., Adelusola K.A., Adefehinti О. et al. Quartan malaria-associated childhood nephrotic syndrome: now a rare clinical entity in malaria endemic Nigeria. Nephrol. Dial. Transplant. 2010; 25: 794-801.
  469. Doe J.Y., Funk M., Mengel M. et al. Nephrotic syndrome in African children: lack of evidence for ‘tropical nephrotic syndrome’? Nephrol. Dial. Transplant. 2006; 21: 672-676.
  470. Seggie J., Davies P.G., Ninin D. et al. Patterns of glomerulonephritis in Zimbabwe: survey of disease characterised by nephrotic proteinuria. Q. J. Med. 1984; 53: 109-118.
  471. Roberts I.S., Cook H.T., Troyanov S. et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76: 546-556.
  472. Li P.K., Ho K.K., Szeto C.C. et al. Prognostic indicators of IgA nephropathy in the Chinese-clinical and pathological perspectives. Nephrol. Dial. Transplant. 2002; 17: 64-69.
  473. Nair R., Walker P.D. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int. 2006; 69: 1455-1458.
  474. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-1305.
  475. Donadio J.V., Bergstralh E.J., Grande J.P. et al. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol. Dial. Transplant. 2002; 17: 1197-1203.
  476. Geddes C.C., Rauta V., Gronhagen-Riska С. et al. A tricontinental view of IgA nephropathy. Nephrol. Dial. Transplant. 2003; 18: 1541-1548.
  477. Goto M., Wakai K., Kawamura T. et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol. Dial. Transplant. 2009; 24: 3068-3074.
  478. Reich H.N., Troyanov S., Scholey J.W. et al. Remission of proteinuria improves prognosis in IgA nephropathy. J. Am. Soc. Nephrol. 2007; 18: 3177-3183.
  479. Coppo R., Peruzzi L., Amore A. et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J. Am. Soc. Nephrol. 2007; 18: 1880-1888.
  480. Cattran D.C., Coppo R., Cook H.T. et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76: 534-545.
  481. Szeto C.C., Lai F.M., To K.F. et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am. J. Med. 2001; 110: 434-437.
  482. Coppo R., D’Amico G. Factors predicting progression of IgA nephropathies. J. Nephrol. 2005; 18: 503-512.
  483. Frisch G., Lin J., Rosenstock J. et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol. Dial. Transplant. 2005; 20: 2139-2145.
  484. Harmankaya O., Ozturk Y., Basturk T. et al. Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria. Int. Urol. Nephrol. 2002; 33: 167-171.
  485. Bartosik L.P., Lajoie G., Sugar L. et al. Predicting progression in IgA nephropathy. Am. J. Kidney. Dis. 2001; 38: 728-735.
  486. Kanno Y., Okada H., Saruta T. et al. Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin. Nephrol. 2000; 54: 360-365.
  487. Jafar T.H., Schmid C.H., Landa M. et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 2001; 135: 73-87.
  488. Sarafidis P.A., Khosla N., Bakris G.L. Antihypertensive therapy in the presence of proteinuria. Am. J. Kidney. Dis. 2007; 49: 12-26.
  489. Fellin G., Gentile M.G., Duca G. et al. Renal function in IgA nephropathy with established renal failure. Nephrol. Dial. Transplant. 1988; 3: 17-23.
  490. Ballardie F.W., Roberts I.S. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J. Am. Soc. Nephrol. 2002; 13: 142-148.
  491. Rekola S., Bergstrand A., Bucht H. Deterioration of GFR in IgA nephropathy as measured by 51Q-EDTA clearance. Kidney Int. 1991; 40: 1050-1054.
  492. D’Amico G., Minetti L., Ponticelli С. et al. Prognostic indicators in idiopathic IgA mesangial nephropathy. Q. J. Med. 1986; 59: 363-378.
  493. Boyce N.W., Holdsworth S.R., Thomson N.M. et al. Clinicopathological associations in mesangial IgA nephropathy. Am. J. Nephrol. 1986; 6: 246-252.
  494. Freese P., Norden G., Nyberg G. Morphologic high-risk factors in IgA nephropathy. Nephron. 1998; 79: 420-425.
  495. Hogg R.J., Silva F.G., Wyatt R.J. et al. Prognostic indicators in children with IgA nephropathy-report of the Southwest Pediatric Nephrology Study Group. Pediatr. Nephrol. 1994; 8: 15-20.
  496. Tumlin J.A., Lohavichan V., Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol. Dial. Transplant. 2003; 18: 1321-1329.
  497. Katafuchi R., Oh Y., Hori К. et al. An important role of glomerular segmental lesions on progression of IgA nephropathy: a multivariate analysis. Clin. Nephrol. 1994; 41: 191-198.
  498. Packham D.K., Yan H.D., Hewitson T.D. et al. The significance of focal and segmental hyalinosis and sclerosis (FSHS) and nephrotic range proteinuria in IgA nephropathy. Clin. Nephrol. 1996; 46: 225-229.
  499. Hsu C.Y., McCulloch C.E., Iribarren С. et al. Body mass index and risk for end-stage renal disease. Ann. Intern. Med. 2006; 144: 21-28.
  500. Navaneethan S.D., Yehnert H., Moustarah F. et al. Weight loss interventions in chronic kidney disease: a systematic review and metaanalysis. Clin. J. Am. Soc. Nephrol. 2009; 4: 1565-1574.
  501. Bonnet F., Deprele C., Sassolas A. et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am. J. Kidney. Dis. 2001; 37: 720-727.
  502. Tanaka M., Tsujii T., Komiya T. et al. Clinicopathological influence of obesity in IgA nephropathy: comparative study of 74 patients. Contrib. Nephrol. 2007; 157: 90-93.
  503. Coppo R., Troyanov S., Camilla R. et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 2010; 77: 921-927.
  504. Rauta V., Finne P., Fagerudd J. et al. Factors associated with progression of IgA nephropathy are related to renal function-a model for estimating risk of progression in mild disease. Clin. Nephrol. 2002; 58: 85-94.
  505. Li P.K., Leung C.B., Chow K.M. et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am. J. Kidney. Dis. 2006; 47: 751-760.
  506. Praga M., Gutierrez E., Gonzalez E. et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J. Am. Soc. Nephrol. 2003; 14: 1578-1583.
  507. Horita Y., Tadokoro M., Taura К. et al. Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. Ren. Fail. 2007; 29: 441-446.
  508. Russo D., Pisani A., Balletta M.M. et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am. J. Kidney. Dis. 1999; 33: 851-856.
  509. Yang Y., Ohta K., Shimizu M. et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin. Nephrol. 2005; 64: 35-40.
  510. Pozzi C., Bolasco P.G., Fogazzi G.B. et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999; 353: 883-887.
  511. Manno C., Torres D.D., Rossini M. et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol. Dial. Transplant. 2009; 24: 3694-3701.
  512. Lv J., Zhang H., Chen Y. et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am. J. Kidney. Dis. 2009; 53: 26-32.
  513. Pozzi C., Andrulli S., Del Vecchio L. et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J. Am. Soc. Nephrol. 2004; 15: 157-163.
  514. Pozzi C., Locatelli F. Corticosteroids in IgA nephropathy (letter). Lancet. 1999; 353: 2159-2160.
  515. Manno C., Gesualdo L., D’Altri С. et al. Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy. J. Nephrol. 2001; 14: 248-252.
  516. Hogg R.J., Lee J., Nardelli N. et al. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin. J. Am. Soc. Nephrol. 2006; 1: 467-474.
  517. Katafuchi R., Ikeda K., Mizumasa T. et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am. J. Kidney. Dis. 2003; 41: 972-983.
  518. Strippoli G.F., Maione A., Schena F.P. et al. IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice. Am. J. Kidney. Dis. 2009; 53: 5-8.
  519. Kobayashi Y., Hiki Y., Kokubo T. et al. Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study. Nephron. 1996; 72: 237-242.
  520. Eitner F., Ackermann D., Hilgers R.D. et al. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. J. Nephrol. 2008; 21: 284-289.
  521. Walker R.G., Yu S.H., Owen J.E. et al. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin. Nephrol. 1990; 34: 103-107.
  522. Woo K.T., Lee G.S. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin. Clin. Nephrol. 1991; 35: 184.
  523. Yoshikawa N., Ito H., Sakai T. et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J. Am. Soc. Nephrol. 1999; 10: 101-109.
  524. Pozzi C., Andrulli S., Pani A. et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J. Am. Soc. Nephrol. 2010; 21: 1783-1790.
  525. Yoshikawa N., Honda M., lijima К. et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin. J. Am. Soc. Nephrol. 2006; 1: 511-517.
  526. Maes B.D., Oyen R., Claes К. et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 2004; 65: 1842-1849.
  527. Tang S., Leung J.C., Chan L.Y. et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005; 68: 802-812.
  528. Tang S.C., Tang A.W., Wong S.S. et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 2010; 77: 543-549.
  529. Lv J., Zhang H., Cui Z. et al. Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol. Dial. Transplant. 2008; 23: 2868-2872.
  530. Donadio Jr J.V., Bergstralh E.J., Offord K.P. et al. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N. Engl. J. Med. 1994; 331: 1194-1199.
  531. Donadio Jr J.V., Grande J.P., Bergstralh E.J. et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J. Am. Soc. Nephrol. 1999; 10: 1772-1777.
  532. Alexopoulos E., Stangou M., Pantzaki A. et al. Treatment of severe IgA nephropathy with omega-3 fatty acids: the effect of a «very low dose» regimen. Ren. Fail. 2004; 26: 453-459.
  533. Ferraro P.M., Ferraccioli G.F., Gambaro G. et al. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol. Dial. Transplant. 2009; 24: 156-160.
  534. Bennett W.M., Walker R.G., Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial. Clin. Nephrol. 1989; 31: 128-131.
  535. Pettersson Е.Е., Rekola S., Berglund L. et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin. Nephrol. 1994; 41: 183-190.
  536. Strippoli G.F., Manno C., Schena F.P. An «evidence-based» survey of therapeutic options for IgA nephropathy: assessment and criticism. Am. J. Kidney. Dis. 2003; 41: 1129-1139.
  537. Miller III E.R., Juraschek S.P., Appel L.J. et al. The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials. Am. J. Clin. Nutr. 2009; 89: 1937-1945.
  538. Hogg R.J., Fitzgibbons L., Atkins С. et al. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent. Clin. J. Am. Soc. Nephrol. 2006; 1: 1167-1172.
  539. Donadio Jr J.V., Larson T.S., Bergstralh E.J. et al. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J. Am. Soc. Nephrol. 2001; 12: 791-799.
  540. Taji Y., Kuwahara T., Shikata S. et al. Meta-analysis of antiplatelet therapy for IgA nephropathy. Clin. Exp. Nephrol. 2006; 10: 268-273.
  541. Hotta O., Miyazaki M., Furuta T. et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am. J. Kidney. Dis. 2001; 38: 736-743.
  542. Xie Y., Nishi S., Ueno M. et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int. 2003; 63: 1861-1867.
  543. Komatsu H., Fujimoto S., Hara S. et al. Effect of tonsillectomy plus steroid pulse therapy on clinical remission of IgA nephropathy: a controlled study. Clin. J. Am. Soc. Nephrol. 2008; 3: 1301-1307.
  544. Rasche F.M., Schwarz A., Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin. Nephrol. 1999; 51: 147-152.
  545. Kim S.M., Moon К.С., Oh K.H. et al. Clinicopathologic characteristics of IgA nephropathy with steroid-responsive nephrotic syndrome. J. Korean. Med. Sci. 2009; 24 (Suppl): S44-S49.
  546. Lai K.N., Lai F.M., Chan K.W. et al. An overlapping syndrome of IgA nephropathy and lipoid nephrosis. Am. J. Clin. Pathol. 1986; 86: 716-723.
  547. Lai K.N., Lai F.M., Ho C.P. et al. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin. Nephrol. 1986; 26: 174-180.
  548. Gutierrez E., Gonzalez E., Hernandez E. et al. Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin. J. Am. Soc. Nephrol. 2007; 2: 51-57.
  549. Praga M., Gutierrez-Millet V., Navas J.J. et al. Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy. Kidney Int. 1985; 28: 69-74.
  550. Bennett W.M., Kincaid-Smith P. Macroscopic hematuria in mesangial IgA nephropathy: correlation with glomerular crescents and renal dysfunction. Kidney Int. 1983; 23: 393-400.
  551. Abe T., Kida H., Yoshimura M. et al. Participation of extracapillary lesions (ECL) in progression of IgA nephropathy. Clin. Nephrol. 1986; 25: 37-41.
  552. Tang Z., Wu Y., Wang Q.W. et al. Idiopathic IgA nephropathy with diffuse crescent formation. Am. J. Nephrol. 2002; 22: 480-486.
  553. Pankhurst T., Lepenies J., Nightingale P. et al. Vasculitic IgA nephropathy: prognosis and outcome. Nephron. Clin. Pract. 2009; 112: c16-c24.
  554. Coppo R., Basolo B., Roccatello D. et al. Plasma exchange in progressive primary IgA nephropathy. Int. J. Artif. Organs. 1985; 8(Suppl. 2): 55-58.
  555. Saulsbury F.T. Clinical update: Henoch-Schonlein purpura. Lancet. 2007; 369: 976-978.
  556. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch. Dis. Child. 2005; 90: 916-920.
  557. Saulsbury F.T. Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore). 1999; 78: 395-409.
  558. Shin J.l., Park J.M., Shin Y.H. et al. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schonlein purpura. Scand. J. Rheumatol. 2006; 35: 56-60.
  559. Goldstein A.R., White R.H., Akuse R. et al. Long-term follow-up of childhood Henoch-Schonlein nephritis. Lancet. 1992; 339: 280-282.
  560. Edstrom Hailing S., Soderberg M.P., Berg U.B. Predictors of outcome in Henoch-Schonlein nephritis. Pediatr. Nephrol. 2010; 25: 1101-1108.
  561. Ronkainen J., Nuutinen M., Koskimies O. The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study. Lancet. 2002; 360: 666-670.
  562. Zaffanello M., Fanos V. Treatment-based literature of Henoch-Schonlein purpura nephritis in childhood. Pediatr. Nephrol. 2009; 24: 1901-1911.
  563. Ronkainen J., Koskimies O., Ala-Houhala M. et al. Early prednisone therapy in Henoch-Schonlein purpura: a randomized, double-blind, placebo-controlled trial. J. Pediatr. 2006; 149: 241-247.
  564. Niaudet P., Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch purpura nephritis. Pediatr. Nephrol. 1998; 12: 238-243.
  565. Foster B.J., Bernard C., Drummond K.N. et al. Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J. Pediatr. 2000; 136: 370-375.
  566. Tarshish P., Bernstein J., Edelmann Jr C.M. Henoch-Schonlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr. Nephrol. 2004; 19: 51-56.
  567. Kawasaki Y., Suzuki J., Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schonlein nephritis: a clinical and histopathological study. Nephrol. Dial. Transplant. 2004; 19: 858-864.
  568. Ronkainen J., Ala-Houhala M., Antikainen M. et al. Cyclosporine A (CyA) versus MP pulses (MP) in the treatment of severe Henoch-Schonlein Nephritis (HSN) (abstract). Pediatr. Nephrol. 2006; 21: 1531.
  569. Jauhola O., Ronkainen J., Ala-Houhala M. et al. Cyclosporine A (CyA) versus MP pulses in severe Henoch-Schonlein Nephritis (HSN): Outcome after 2 year follow up (abstract). Pediatr. Nephrol. 2008; 23: 1584.
  570. Bergstein J., Leiser J., Andreoli S.P. Response of crescentic Henoch-Schonlein purpura nephritis to corticosteroid and azathioprine therapy. Clin. Nephrol. 1998; 49: 9-14.
  571. Flynn J.T., Smoyer W.E., Bunchman Т.Е. et al. Treatment of Henoch-Schonlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am. J. Nephrol. 2001; 21: 128-133.
  572. Ronkainen J., Autio-Harmainen H., Nuutinen M. Cyclosporin A for the treatment of severe Henoch-Schonlein glomerulonephritis. Pediatr. Nephrol. 2003; 18: 1138-1142.
  573. Shin J.l., Park J.M., Shin Y.H. et al. Cyclosporin A therapy for severe Henoch-Schonlein nephritis with nephrotic syndrome. Pediatr. Nephrol. 2005; 20: 1093-1097.
  574. Kawasaki Y., Suzuki J., Murai M. et al. Plasmapheresis therapy for rapidly progressive Henoch-Schonlein nephritis. Pediatr. Nephrol. 2004; 19: 920-923.
  575. Shenoy M., Ognjanovic M.V., Coulthard M.G. Treating severe Henoch-Schonlein and IgA nephritis with plasmapheresis alone. Pediatr. Nephrol. 2007; 22: 1167-1171.
  576. Fuentes Y., Valverde S., Valesquez-Jones L. et al. Comparison of azathioprine vs mofetil mycophenolate for Henoch-Schonlein nephritis treatment (abstract). Pediatr. Nephrol. 2010; 25: 1802.
  577. Chartapisak W., Opastiraku S., Willis N.S. et al. Prevention and treatment of renal disease in Henoch-Schonlein purpura: a systematic review. Arch. Dis. Child. 2009; 94: 132-137.
  578. Chartapisak W., Opastirakul S., Hodson E.M. et al. Interventions for preventing and treating kidney disease in Henoch-Schonlein Purpura (HSP). Cochrane Database Syst. Rev. 2009: CD005128.
  579. Dudley J., Smith G., Llewellyn-Edwards A. et al. Randomised placebo controlled trial to assess the role of early prednisolone on the development and progression of Henoch-Schonlein Purpura Nephritis (abstract). Pediatr. Nephrol. 2007; 22: 1457.
  580. Blanco R., Martinez-Taboada V.M., Rodriguez-Valverde V. et al. Henoch-Schonlein purpura in adulthood and childhood: two different expressions of the same syndrome. Arthritis. Rheum. 1997; 40: 859-864.
  581. Coppo R., Andrulli S., Amore A. et al. Predictors of outcome in Henoch-Schonlein nephritis in children and adults. Am. J. Kidney. Dis. 2006; 47: 993-1003.
  582. Shrestha S., Sumingan N., Tan J. et al. Henoch- Schonlein purpura with nephritis in adults: adverse prognostic indicators in a UK population. QJM. 2006; 99: 253-265.
  583. Rauta V., Tornroth T., Gronhagen-Riska С. Henoch-Schonlein nephritis in adults-clinical features and outcomes in Finnish patients. Clin. Nephrol. 2002; 58: 1-8.
  584. Hung S.P., Yang Y.H., Lin Y.T. et al. Clinical manifestations and outcomes of Henoch-Schonlein purpura: comparison between adults and children. Pediatr Neonatol. 2009; 50: 162-168.
  585. Pillebout E., Thervet E., Hill G. et al. Henoch-Schonlein Purpura in adults: outcome and prognostic factors. J. Am. Soc. Nephrol. 2002; 13:1271-1278.
  586. Pillebout E., Alberti C., Guillevin L. et al. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch-Schonlein Purpura. Kidney Int. 2010; 78: 495-502.
  587. Campbell Jr R., Cooper G.S., Gilkeson G.S. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. Arthritis. Rheum. 2008; 59: 458-464.
  588. Danila M.l., Pons-Estel G.J., Zhang J. et al. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford). 2009; 48: 542-545.
  589. Font J., Ramos-Casals M., Cervera R. et al. Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM. 2001; 94: 19-26.
  590. Al Arfaj A.S., Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus. 2009; 18: 465-473.
  591. Bastian H.M., Roseman J.M., McGwin Jr G. et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002; 11: 152-160.
  592. Seligman V.A., Lum R.F., Olson J.L. et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am. J. Med. 2002; 112: 726-729.
  593. Ward M.M. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J. Rheumatol. 2009; 36: 63-67.
  594. Adler M., Chambers S., Edwards С. et al. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford). 2006; 45: 1144-1147.
  595. Al Arfaj A.S., Khalil N., Al Saleh S. Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia. Rheumatol.Int. 2009; 29: 1057-1067.
  596. Gonzalez-Crespo M.R., Lopez-Fernandez Jl., Usera G. et al. Outcome of silent lupus nephritis. Semin. Arthritis. Rheum. 1996; 26: 468-476.
  597. Valente de Almeida R., Rocha de Carvalho J.G., de Azevedo V.F. et al. Microalbuminuria and renal morphology in the evaluation of subclinical lupus nephritis. Clin. Nephrol. 1999; 52: 218-229.
  598. Zabaleta-Lanz M.E., Munoz L.E., Tapanes F.J. et al. Further description of early clinically silent lupus nephritis. Lupus. 2006; 15: 845-851.
  599. Kraft S.W., Schwartz M.M., Korbet S.M. et al. Glomerular podocytopathy in patients with systemic lupus erythematosus. J. Am. Soc. Nephrol. 2005; 16: 175-179.
  600. Austin III H.A., Klippel J.H., Balow J.E. et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 1986; 314: 614-619.
  601. Boumpas D.T., Austin III H.A., Vaughn E.M. et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992; 340: 741-745.
  602. Donadio Jr J.V., Holley K.E., Ferguson R.H. et al. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl. J. Med. 1978; 299: 1151-1155.
  603. Gourley M.F., Austin III H.A., Scott D. et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. 1996; 125: 549-557.
  604. Houssiau F.A., Vasconcelos C., D’Cruz D. et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann. Rheum. Dis. 2010; 69: 61-64.
  605. Houssiau F.A., Vasconcelos C., D’Cruz D. et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis. Rheum. 2002; 46: 2121-2131.
  606. McKinley A., Park E., Spetie D. et al. Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. Clin. J. Am. Soc. Nephrol. 2009; 4: 1754-1760.
  607. Moroni G., Doria A., Mosca M. et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin. J. Am. Soc. Nephrol.2006; 1: 925-932.
  608. Chan T.M., Tse К.С., Tang C.S. et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus. 2005; 14: 265-272.
  609. Мок C.C., Ho C.T., Chan K.W. et al. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis. Rheum. 2002; 46: 1003-1013.
  610. Мок C.C., Ho C.T., Siu Y.P. et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am. J. Kidney. Dis. 2001; 38: 256-264.
  611. Moroni G., Quaglini S., Gallelli В. et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol. Dial. Transplant. 2007; 22: 2531-2539.
  612. Chan T.M., Li F.K., Tang C.S. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 2000; 343: 1156-1162.
  613. Chan T.M., Tse К.С., Tang C.S. et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 2005; 16: 1076-1084.
  614. Appel G.B., Contreras G., Dooley M.A. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 2009; 20: 1103-1112.
  615. Traitanon O., Avihingsanon Y., Kittikovit V. et al. Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus. 2008; 17: 744-751.
  616. Grootscholten C., Ligtenberg G., Hagen E.C. et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006; 70: 732-742.
  617. Grootscholten C., Bajema I.M., Florquin S. et al. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis. Rheum. 2007; 56: 924-937.
  618. Zavada J., Pesickova S., Rysava R. et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010; 19: 1281-1289.
  619. Bao H., Liu Z.H., Xie H.L. et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J. Am. Soc. Nephrol. 2008; 19: 2001-2010.
  620. Balow J.E., Austin III H.A., Muenz L.R. et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N. Engl. J. Med. 1984; 311: 491-495.
  621. Haubitz M., Bohnenstengel F., Brunkhorst R. et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002; 61: 1495-1501.
  622. Pendse S., Ginsburg E., Singh A.K. Strategies for preservation of ovarian and testicular function after immunosuppression. Am. J. Kidney. Dis. 2004; 43: 772-781.
  623. Somers E.C., Marder W., Christman G.M. et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis. Rheum. 2005; 52: 2761-2767.
  624. Ginzler E.M., Dooley M.A., Aranow С. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 2005; 353: 2219-2228.
  625. Hu W., Liu Z., Chen H. et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin. Med. J. (Engl.) 2002; 115: 705-709.
  626. Ong L.M., Hooi L.S., Lim T.O. et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton). 2005; 10: 504-510.
  627. El-Shafey E.M., Abdou S.H., Shareef M.M. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin. Exp. Nephro. 2010; 14: 214-221.
  628. Korbet S.M., Schwartz M.M., Evans J. et al. Severe lupus nephritis: racial differences in presentation and outcome. J. Am. Soc. Nephrol. 2007; 18: 244-254.
  629. Rovin B.H., Appel G.B., Furie R.A. et al. Efficacy and safety of rituximab (RTX) in subjects with proliferative lupus nephritis (LN): Results from the randomized, double-blind, phase III LUNAR study (abstract). J. Am. Soc. Nephrol. 2009; 20: 77A.
  630. Gunnarsson I., Sundelin B., Jonsdottir T. et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis. Rheum. 2007; 56: 1263-1272.
  631. Karim M.Y., Pisoni C.N., Khamashta M.A. Update on immunotherapy for systemic lupus erythematosus-what’s hot and what’s not! Rheumatology (Oxford). 2009; 48: 332-341.
  632. Li E.K., Tarn L.S., Zhu T.Y. et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford). 2009; 48: 892-898.
  633. Lu T.Y., Ng K.P., Cambridge G. et al. A retrospective seven-year analysis of the use of В cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis. Rheum. 2009; 61: 482-487.
  634. Ramos-Casals M., Soto M.J., Cuadrado M.J. et al. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus. 2009; 18: 767-776.
  635. Sousa E., Isenberg D. Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies. Sesf. Pract. Res. Clin. Rheumatol. 2009; 23: 563-574.
  636. Tieng A.T., Peeva E. B-cell-directed therapies in systemic lupus erythematosus. Semin. Arthritis. Rheum. 2008; 38: 218-227.
  637. Cameron J.S., Turner D.R., Ogg C.S. et al. Systemic lupus with nephritis: a long-term study. Q. J. Med. 1979; 48: 1-24.
  638. Jayne DR.W., Appel G.B., Dooley M.A. et al. Results of the Aspreva Lupus Management Study (ALMS) maintenance phase (abstract). J. Am. Soc. Nephrol. 2010; 21: 25A.
  639. Contreras G., Pardo V., Leclercq В. et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 2004; 350: 971-980.
  640. Houssiau F.A., D’Cruz D., Sangle S. et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 2010; 69: 2083-2089.
  641. Griffiths B., Emery P., Ryan V. et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford). 2010; 49: 723-732.
  642. Gunnarsson I., Sundelin B., Heimburger M. et al. Repeated renal biopsy in proliferative lupus nephritis-predictive role of serum Ciq and albuminuria. J. Rheumatol. 2002; 29: 693-699.
  643. Hill G.S., Delahousse M., Nochy D. et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 2001; 59: 304-316.
  644. loannidis J.P., Boki K.A., Katsorida M.E. et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000; 57: 258-264.
  645. Moroni G., Pasquali S., Quaglini S. et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am. J. Kidney. Dis. 1999; 34: 530-539.
  646. Chen Y.E., Korbet S.M., Katz R.S. et al. Value of a complete or partial remission in severe lupus nephritis. Clin. J. Am. Soc. Nephrol.2008; 3: 46-53.
  647. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am. J. Kidney. Dis. 1992; 19: 473-479.
  648. Barr R.G., Seliger S., Appel G.B. et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol. Dial. Transplant. 2003; 18: 2039-2046.
  649. Contreras G., Pardo V., Cely С. et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005; 14: 890-895.
  650. Gibson K.L., Gipson D.S., Massengill S.A. et al. Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin. J. Am. Soc. Nephrol.2009; 4: 1962-1967.
  651. Rovin B.H., Zhang X. Biomarkers for lupus nephritis: the quest continues. Clin. J. Am. Soc. Nephrol.2009; 4: 1858-1865.
  652. Hebert L.A., Wilmer W.A., Falkenhain M.E. et al. Renoprotection: one or many therapies? Kidney Int. 2001; 59: 1211-1226.
  653. Wilmer W.A., Rovin B.H., Hebert C.J. et al. Management of glomerular proteinuria: a commentary. J. Am. Soc. Nephrol. 2003; 14: 3217-3232.
  654. Coremans I.E., Spronk P.E., Bootsma H. et al. Changes in antibodies to Ciq predict renal relapses in systemic lupus erythematosus. Am. J. Kidney. Dis. 1995; 26: 595-601.
  655. Esdaile J.M., Abrahamowicz M., Joseph L. et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis. Rheum. 1996; 39: 370-378.
  656. Esdaile J.M., Joseph L., Abrahamowicz M. et al. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J. Rheumatol. 1996; 23: 1891-1896.
  657. Ho A., Barr S.G., Magder L.S. et al. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis. Rheum. 2001; 44: 2350-2357.
  658. Ho A., Magder L.S., Barr S.G. et al. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis. Rheum. 2001; 44: 2342-2349.
  659. Moroni G., Radice A., Giammarresi G. et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann. Rheum. Dis. 2009; 68: 234-237.
  660. Rovin B.H., Birmingham D.J., Nagaraja H.N. et al. Biomarker discovery in human SLE nephritis. Bull. NYU Hosp. Jt. Dis. 2007; 65: 187-193.
  661. Giatras I., Lau J., Levey A.S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann. Intern. Med. 1997; 127: 337-345.
  662. Mercadal L., Montcel S.T., Nochy D. et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol. Dial. Transplant. 2002; 17: 1771-1778.
  663. Мок С.С. Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma. Nat. Rev. Nephrol. 2009; 5: 212-220.
  664. Мок С.С., Ying K.Y., Yim C.W. et al. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine. Lupus. 2009; 18: 1091-1095.
  665. Pasquali S., Banfi G., Zucchelli A. et al. Lupus membranous nephropathy: long-term outcome. Clin. Nephrol. 1993; 39: 175-182.
  666. Sloan R.P., Schwartz M.M., Korbet S.M. et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J. Am. Soc. Nephrol. 1996; 7: 299-305.
  667. Donadio Jr J.V., Burgess J.H., Holley K.E. Membranous lupus nephropathy: a clinicopathologic study. Medicine (Baltimore). 1977; 56: 527-536.
  668. Gonzalez-Dettoni H., Tron F. Membranous glomerulopathy in systemic lupus erythematosus. Adv. Nephrol. Necker. Hosp. 1985; 14: 347-364.
  669. Ordonez J.D., Hiatt R.A., Killebrew E.J. et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993; 44: 638-642.
  670. Мок С.С., Ying K.Y., Lau C.S. et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am. J. Kidney. Dis. 2004; 43: 269-276.
  671. Austin III H.A., Illei G.G., Braun M.J. et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J. Am. Soc. Nephrol. 2009; 20: 901-911.
  672. Kasitanon N., Petri M., Haas M. et al. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. Lupus. 2008; 17: 40-45.
  673. Spetie D.N., Tang Y., Rovin B.H. et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int. 2004; 66: 2411-2415.
  674. Szeto C.C., Kwan В.С., Lai F.M. et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008; 47: 1678-1681.
  675. Ruiz-lrastorza G., Ramos-Casals M., Brito-Zeron P. et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 2010; 69: 20-28.
  676. Tsakonas E., Joseph L., Esdaile J.M. et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998; 7: 80-85.
  677. Siso A., Ramos-Casals M., Bove A. et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus. 2008; 17: 281-288.
  678. Kaiser R., Cleveland C.M., Criswell L.A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi ethnic cohort. Ann. Rheum. Dis. 2009; 68: 238-241.
  679. Pons-Estel G.J., Alarcon G.S., McGwin Jr G. et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis. Rheum. 2009; 61: 830-839.
  680. Illei G.G., Takada K., Parkin D. et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis. Rheum. 2002; 46: 995-1002.
  681. Esdaile J.M., Joseph L., MacKenzie T. et al. The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy. Semin Arthritis. Rheum. 1993; 23: 135-148.
  682. Daleboudt G.M.N., Bajema I.M., Goemaere N.N.T. et al. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol. Dial. Transplant. 2009; 24: 3712-3717.
  683. Birmingham D.J., Nagaraja H.N., Rovin B.H. et al. Fluctuation in self-perceived stress and increased risk of flare in patients with lupus nephritis carrying the serotonin receptor 1A-1019 G allele. Arthritis. Rheum. 2006; 54: 3291-3299.
  684. Clough J.D., Lewis E.J., Lachin J.M. Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Prog. Clin. Biol. Res. 1990; 337: 301-307.
  685. Linnik M.D., Hu J.Z., Heilbrunn K.R. et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis. Rheum. 2005; 52: 1129-1137.
  686. Rovin B.H., Song H., Birmingham D.J. et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J. Am. Soc. Nephrol. 2005; 16: 467-473.
  687. Rovin B.H., Nadasdy G., Nuovo G.J. et al. Expression of adiponectin and its receptors in the kidney during SLE nephritis (abstract). J. Am. Soc. Nephrol. 2006; 17: 256A.
  688. Rovin B.H., Stillman I.E. Kidney. In: Lahita R.G., Tsokos G.T., Buyon J.P., Koike T. (eds). Systemic Lupus Erythematosus, 5th edn. Elsevier: Waltham, MA, 2011; 769-814.
  689. Garcia-Carrasco M., Mendoza-Pinto C., Sandoval-Cruz M. et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus. 2010; 19: 213-219.
  690. Rauova L., Lukac J., Levy Y. et al. High-dose intravenous immunoglobulins for lupus nephritis - a salvage immunomodulation. Lupus. 2001; 10: 209-213.
  691. Ogawa H., Kameda H., Amano К. et al. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010; 19: 162-169.
  692. Ogawa H., Kameda H., Nagasawa H. et al. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod. Rheumatol. 2007; 17: 92-97.
  693. Miyasaka N., Kawai S., Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod. Rheumatol. 2009; 19: 606-615.
  694. Daugas E., Nochy D., Huong D.L. et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J. Am. Soc. Nephrol. 2002; 13: 42-52.
  695. Tektonidou M.G. Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. Clin. Rev. Allergy. Immunol. 2009; 36: 131-140.
  696. Tektonidou M.G., Sotsiou F., Moutsopoulos H.M. Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J. Rheumatol. 2008; 35: 1983-1988.
  697. Crowther M.A., Ginsberg J.S., Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 2003; 349: 1133-1138.
  698. Finazzi G., Marchioli R., Brancaccio V. et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. 2005; 3: 848-853.
  699. Kwok S.K., Ju J.H., Cho C.S. et al. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus. 2009; 18: 16-21.
  700. Tandon A., Ibanez D., Gladman D.D. et al. The effect of pregnancy on lupus nephritis. Arthritis. Rheum. 2004; 50: 3941-3946.
  701. Carvalheiras G., Vita P., Marta S. et al. Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution. Clin. Rev. Allergy. Immunol. 2010; 38: 302-306.
  702. Imbasciati E., Tincani A., Gregorini G. et al. Pregnancy in women with preexisting lupus nephritis: predictors of fetal and maternal outcome. Nephrol. Dial. Transplant. 2009; 24: 519-525.
  703. Wagner S.J., Craici I., Reed D. et al. Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus. 2009; 18: 342-347.
  704. Levy R.A., Vilela V.S., Cataldo M.J. et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001; 10: 401-404.
  705. Hogan S.L., Nachman P.H., Wilkman A.S. et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. 1996; 7: 23-32.
  706. de Groot K., Harper L., Jayne D.R. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 2009; 150: 670-680.
  707. Hogan S.L., Falk R.J., Chin H. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 2005; 143: 621-631.
  708. Jayne D.R., Gaskin G., Rasmussen N. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 2007; 18: 2180-2188.
  709. de Lind van Wijngaarden R.A., Hauer H.A., Wolterbeek R. et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 2007; 18: 2189-2197.
  710. Nachman P.H., Hogan S.L., Jennette J.C. et al. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. 1996; 7: 33-39.
  711. Walters G.D., Willis N.S., Craig J.C. Interventions for renal vasculitis in adults. A systematic review. ВМС Nephrol. 2010; 11: 12.
  712. Jayne D., Rasmussen N., Andrassy К. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 2003; 349: 36-44.
  713. Guillevin L., Cohen P., Mahr A. et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis. Rheum. 2003; 49: 93-100.
  714. Jones R.B., Tervaert J.W., Hauser T. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N.Engl. J. Med. 2010; 363: 211-220.
  715. Stone J.H., Merkel P.A., Spiera R. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 2010; 363: 221-232.
  716. Cole E., Cattran D., Magil A. et al. A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am. J. Kidney. Dis. 1992; 20: 261-269.
  717. Lauque D., Cadranel J., Lazor R. et al. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d’Etudes et de Recherche sur les Maladies «Orphelines» Pulmonaires (GERM«O»P). Medicine (Baltimore). 2000; 79: 222-233.
  718. Klemmer P.J., Chalermskulrat W., Reif M.S. et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am. J. Kidney. Dis. 2003; 42: 1149-1153.
  719. Holguin F., Ramadan B., Gal A.A. et al. Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. Am. J. Med. Sci. 2008; 336: 321-326.
  720. Rutgers A., Slot M., van Paassen P. et al. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am. J. Kidney. Dis. 2005; 46: 253-262.
  721. Silva F., Specks U., Kalra S. et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement - a prospective, open-label pilot trial. Clin. J. Am. Soc. Nephrol.2010; 5: 445-453.
  722. Stassen P.M., Tervaert J.W., Stegeman C.A. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann. Rheum. Dis. 2007; 66: 798-802.
  723. Hu W., Liu C., Xie H. et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol. Dial. Transplant. 2008; 23: 1307-1312.
  724. Sanders J.S., Huitma M.G., Kallenberg C.G. et al. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford). 2006; 45: 724-729.
  725. Hiemstra T.F., Walsh M., Mahr A. et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010; 304: 2381-2388.
  726. Stegeman C.A., Tervaert J.W., de Jong P.E. et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N. Engl. J. Med. 1996; 335: 16-20.
  727. Pagnoux C., Mahr A., Hamidou M.A. et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 2008; 359: 2790-2803.
  728. Lionaki S., Hogan S.L., Jennette C.E. et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 2009; 76: 644-651.
  729. Weidanz F., Day C.J., Hewins P. et al. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am. J. Kidney. Dis. 2007; 50: 36-46.
  730. Martinez V., Cohen P., Pagnoux С. et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis. Rheum. 2008; 58: 308-317.
  731. Dickenmann M., Oettl T., Mihatsch M.J. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am. J. Kidney. Dis. 2008; 51: 491-503.
  732. Jayne D.R., Chapel H., Adu D. et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000; 93: 433-439.
  733. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. 2005; 257: 540-548.
  734. Keogh K.A., Wylam M.E., Stone J.H. et al. Induction of remission by В lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis. Rheum. 2005; 52: 262-268.
  735. Stasi R., Stipa E., Del Poeta G. et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2006; 45: 1432-1436.
  736. Finkielman J.D., Merkel P.A., Schroeder D. et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann. Intern. Med. 2007; 147: 611-619.
  737. Nowack R., Grab I., Flores-Suarez L.F. et al. ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 2001; 16: 1631-1637.
  738. Gera M., Griffin M.D., Specks U. et al. Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int. 2007; 71: 1296-1301.
  739. Nachman P.H., Segelmark M., Westman К. et al. Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kidney Int. 1999; 56: 1544-1550.
  740. Little M.A., Hassan B., Jacques S. et al. Renal transplantation in systemic vasculitis: when is it safe? Nephrol. Dial. Transplant. 2009; 24: 3219-3225.
  741. Levy J.B., Turner A.N., Rees A.J. et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann. Intern. Med. 2001; 134: 1033-1042.
  742. Johnson J.P., Moore Jr J., Austin III H.A. et al. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 1985; 64: 219-227.
  743. Jindal K.K. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int. Suppl 1999; 70: S33-S40.
  744. Cui Z., Zhao M.H., Xin G. et al. Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron. Clin. Pract. 2005; 99: c49-c55.
  745. Levy J.B., Hammad T., Coulthart A. et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004; 66: 1535-1540.
  746. Li F.K., Tse К.С., Lam M.F. et al. Incidence and outcome of antiglomerular basement membrane disease in Chinese. Nephrology (Carlton). 2004; 9: 100-104.
  747. Lindic J., Vizjak A., Ferluga D. et al. Clinical outcome of patients with coexistent antineutrophil cytoplasmic antibodies and antibodies against glomerular basement membrane. Ther. Apher. Dial. 2009; 13: 278-281.
  748. Segelmark M., Hellmark T., Wieslander J. The prognostic significance in Goodpasture’s disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron. Clin. Pract. 2003; 94: C59-C68.
  749. Hirayama K., Yamagata K., Kobayashi M. et al. Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin. Exp. Nephrol. 2008; 12: 339-347.
  750. Shah M.K., Hugghins S.Y. Characteristics and outcomes of patients with Goodpasture’s syndrome. South Med. J. 2002; 95: 1411-1418.
  751. Stegmayr B.G., Almroth G., Berlin G. et al. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. Int. J. Artif. Organs. 1999; 22: 81-87.
  752. Proskey A.J., Weatherbee L., Easterling R.E. et al. Goodpasture’s syndrome. A report of five cases and review of the literature. Am. J. Med. 1970; 48: 162-173.
  753. Levy J.B., Lachmann R.H., Pusey C.D. Recurrent Goodpasture’s disease. Am. J. Kidney. Dis. 1996; 27: 573-578.
  754. Adler S., Bruns F.J., Fraley D.S. et al. Rapid progressive glomerulonephritis: relapse after prolonged remission. Arch. Intern. Med. 1981; 141: 852-854.
  755. Hind C.R., Bowman C., Winearls C.G. et al. Recurrence of circulating anti-glomerular basement membrane antibody three years after immunosuppressive treatment and plasma exchange. Clin. Nephrol. 1984; 21: 244-246.
  756. Klasa R.J., Abboud R.T., Ballon H.S. et al. Goodpasture’s syndrome: recurrence after a five-year remission. Case report and review of the literature. Am. J. Med. 1988; 84: 751-755.
  757. Choy B.Y., Chan T.M., Lai K.N. Recurrent glomerulonephritis after kidney transplantation. Am. J. Transplant. 2006; 6: 2535-2542.
  758. Joshi K., Nada R., Minz M. et al. Recurrent glomerulopathy in the renal allograft. Transplant. Proc. 2007; 39: 734-736.
  759. Counsell С. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann. Intern. Med. 1997; 127: 380-387.
  760. Atkins D., Best D., Briss P.A. et al. Grading quality of evidence and strength of recommendations. BMJ. 2004; 328: 1490.
  761. Guyatt G.H., Oxman A.D., Kunz R. et al. Going from evidence to recommendations. BMJ. 2008; 336: 1049-1051.
  762. Uhlig K., Macleod A., Craig J. et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 70: 2058-2065.
  763. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12: 18-23.
  764. Shiffman R.N., Shekelle P., Overhage J.M. et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann. Intern. Med. 2003; 139: 493-498.
  765. Finding what Works in Health Care: Standards for Systematic Reviews. IOM (Institute of Medicine): Washington, DC 2011.
  766. Clinical Practice Guidelines we can Trust. IOM (Institute of Medicine): Washington, DC 2011.

Другие статьи по теме


Навигация по статьям
<< Предыдущая
Следующая >>
Разделы журнала
Наиболее читаемые статьи

Бикбов Б.Т., Томилина Н.А.,  Заместительная терапия больных с хронической почечной недостаточностью в Российской Федерации в 1998-2011 гг. (Отчет по данным Российского регистра заместительной почечной терапии. Часть первая)  7842

Даниел Каттран, Джон Фили, Теренс Кук и соавт.,  Клинические практические рекомендации KDIGO по лечению гломерулонефритов  3013

Земченков А.Ю., Герасимчук Р.П., Сабодаш А.Б.,  Гемодиафильтрация: внимание на объем (Обзор литературы)  2391

Медиана Фильтр (баннер в правом меню) Реклама
Журнал "Нефрология и диализ"
Главная
Последний номер
Архив номеров
Подписка
Контакты
BBraun (нижний баннер) Реклама